WO1991018596A1 - Methods for treating inflammation and compounds and compositions suitable for use therein - Google Patents

Methods for treating inflammation and compounds and compositions suitable for use therein Download PDF

Info

Publication number
WO1991018596A1
WO1991018596A1 PCT/US1991/003319 US9103319W WO9118596A1 WO 1991018596 A1 WO1991018596 A1 WO 1991018596A1 US 9103319 W US9103319 W US 9103319W WO 9118596 A1 WO9118596 A1 WO 9118596A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
alkyl
solution
aryl
mmol
Prior art date
Application number
PCT/US1991/003319
Other languages
French (fr)
Inventor
Moshe Weitzberg
Ronald Martin Burch
Original Assignee
Moshe Weitzberg
Ronald Martin Burch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moshe Weitzberg, Ronald Martin Burch filed Critical Moshe Weitzberg
Priority to CA002083134A priority Critical patent/CA2083134A1/en
Publication of WO1991018596A1 publication Critical patent/WO1991018596A1/en
Priority to NO92924517A priority patent/NO924517L/en
Priority to FI925327A priority patent/FI925327A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Definitions

  • This invention relates to methods for treating inflammatory conditions and to compounds and pharmaceutical compositions suitable for
  • inflammatory conditions such as atopic dermatitis, contact dermatitis, psoriasis, rheumatoid arthritis, glomerulonephritis, osteoarthritis, lupus erythematosis, scleroderma, asthma and irritable bowel disease has, in the past, involved the use of agents such as aspirin-like nonsteroidal anti-inflammatory agents,
  • glucocorticoids methotrexate and cyclophosphamide. Unfortunately these agents generally produce
  • nonsteroidal anti-inflammatory drugs often cause gastrointestinal and renal side effects.
  • Glucocorticoids suppress the immune system, thus producing opportunistic infection and
  • Methotrexate has been associated with patient death
  • cyclophosphamide has
  • the invention also relates to compounds and pharmaceutical
  • compositions suitable for use in such a method are provided.
  • the present invention relates to a method of treating an inflammatory condition comprising administering to an animal in need of such treatment at least one compound of Formula I:
  • X is methylene, ethylene, ethyleneoxy, or oxygen
  • Iipophilic amino acid and Y is -CO 2 H, -CH 2 OH,
  • R 1 and R 7 are hydrogen, alkyl, or aryl;
  • R 3 and R 4 are, independently, hydrogen, alkyl or aryl
  • a and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro;
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of Formula I (above) in an amount sufficient to produce an anti-inflammatory effect, together with a pharmaceutically acceptable carrier.
  • the present invention relates, generally, to compounds of
  • Formula I wherein X, Q, R 3 , R 4 , A and B are defined as set forth above, providing that when R 3 , R 4 , A and B are hydrogen and Y is -C0 7 H (or salt thereof), X is not oxygen, and further providing that when A or B are, independently, hydrogen or halogen, R 3 and R 4 are hydrogen, X is oxygen, and Y is -CO 2 H (or salt thereof), C' is not an aromatic amino acid residue.
  • the invention does, however, include N-[9H-(fluoren- 9-ylmethoxy)carbonyl]-L-tert-leucine and N-[(9H- fluoren-9-ylmethoxy)carbonyl]-L-neopentylglycine.
  • X is methylene, ethylene, ethyleneoxy, or oxygen
  • R 1 and R 3 are hydrogen, alkyl (advantageously, C 1-4 ) or aryl (advantageously, C 6-12 );
  • R 3 and R 4 are, independently, hydrogen, alkyl (advantageously, C 1-4 ) or aryl (advantageously, C 6-12 ); and
  • a and B are, independently, hydrogen, fused phenol, alkyl (advantageously, C 1-9 ), aryl (advantageously, C 6-12 ), alkaryl (advantageously, (C 1-9 )alk(C 6-12 )aryl), aralkyl (advantageously,
  • hydrocarbons can be unsubstituted or substituted with a C 1-4 alkyl group.
  • Iipophilic amino acid as used herein includes within its scope amino acids, the residues of which do not contain free hydroxy groups, free thiol groups, or basic nitrogen atoms.
  • compositions and methods to which the invention relates are provided.
  • one that is preferred for use in the present method is the compound N-[(9H-fluoren-9-ylmethoxy)carbonyl]- L-leucine.
  • N-[(9H-fluoren-9- ylmethoxy)carbonyl]-L-norleucine, and S-benzyl- ⁇ , ⁇ - dimethyl-N-[9H-(fluoren-9-ylmethoxy)carbonyl]-D- cystein are also known compounds that are preferred for use in the present method.
  • novel compounds of Formula I that are preferred for use in the present method are those wherein: i) R 3 , R 4 , A and B are hydrogen, X is methylene, and Q is a Iipophilic amino acid; and ii) R 3 and R 4 are hydrogen, X is oxygen, A and/or B each represents at least one alkyl substituent, and Q is a Iipophilic amino acid.
  • novel compounds of Formula I that are the most preferred for use in the present method are those wherein: i) R 3 and R 4 are hydrogen, X is oxygen, A is a methyl group located in the 4 position of the fluorene ring, B is
  • R 3 and R 4 are hydrogen, X is oxygen, A is a methyl group located in the 4 position of the fluorene ring, B is hydrogen, and Q is the amino acid homophenylalanine; and iii) R 3 and R 4 are hydrogen, X is oxygen, A is a methyl group located in position 2 of the fluorene ring, B is a methyl group located in position 7 of the fluorene ring, and Q is the amino acid leucine.
  • 9H-fluorene can be condensed directly with formaldehyde in the presence of a strong base such as sodium hydride or sodium amide to give the 9-methanol derivative.
  • a strong base such as sodium hydride or sodium amide
  • Compounds in which the alpha carbon atom is substituted may be prepared by reaction between the selected 9H-fluorene and an aldehyde other than formaldehyde or a ketone, such as acetone or acetophenone, in the presence of a strong base.
  • 9H-Fluoren-9-ylmethanols are converted to 9H-fluoren-9-ylmethanol haloformates, carbonates, thiocarbonates, imidylcarbonates or other formate derivatives bearing a grouping ("leaving group") that is readily displaced by a nucleophilic nitrogen of an alpha amino acid.
  • the resulting carbonyl derivatives of an activated 9H-fluoren-9-ylmethanol are condensed with an alpha aminocarboxylic acid to form a 9H-fluoren-9-ylmethoxycarbonyl derivative of the general Formula I.
  • reaction may be effected in a polar organic solvent such as dioxane, tetrahydrofuran, dimethylformamide or pyridine under alkaline conditions (preferably mild) at a low temperature, for example from 0°C to 25°C during a period of from about 2 to 3 hours.
  • a polar organic solvent such as dioxane, tetrahydrofuran, dimethylformamide or pyridine under alkaline conditions (preferably mild) at a low temperature, for example from 0°C to 25°C during a period of from about 2 to 3 hours.
  • a preferred solvent is a mixture of dioxane and water.
  • the N-[(9H-fluoren-9-ylmethoxy)carbonyl]- amino acid precipitates from solution and may be purified, for example, by recrystallization.
  • Utilization of other "leaving groups” may require somewhat elevated temperatures, for example, 25°C to 50°C and longer reaction times, for example, 8 to 12 hours.
  • Typical salts include the alkali metal or alkaline earth salts, although it will be appreciated that other nontoxic salts can also be used.
  • compounds suitable for use in the present method this invention are administered as sodium, potassium, ammonium, choline or
  • the compounds of this invention can be present as D or L optical isomers or, in some cases, as
  • the compounds of Formula I include all isomers of such compounds, whether separated or mixtures thereof.
  • a compound of Formula I as an anti-inflammatory agent can be demonstrated in animals, such as mice, for example, by measuring the ability of the compound to inhibit edema caused by a variety of inflammatory agents that are generally accepted as producing irritation by differing mechanisms.
  • inflammatory agents typically include tetradecanoylphorbolacetate, arachidonic acid, xylene, capsaicin, oxazolone, carrageenan and the like.
  • the reverse passive Arthus test offers another measure of the compound's utility in
  • Test compounds are typically administered intraperitoneally or topically.
  • the test compound can be given in dimethyl sulfoxide or in 0.5% methylcellulose 30 minutes prior to
  • test compound can be dissolved in, for example, acetone, ethanol or dimethyl sulfoxide and applied about 15 minutes prior to application of the irritant. Results can be
  • non-steroidal anti-inflammatory agents operate by a single mechanism (cyclo-oxygenase inhibitors), thus, they are highly active in a single assay (steroids are usually active in most, if not all, screens but have side effects that prohibit their widespread use).
  • the compounds of Formula I are highly active in almost all of the inflammatory screens and are also highly active in the reverse passive artus assay and in adjuvant arthritis, which are
  • the compounds of Formula I have the steroid-like spectrum of activity but lack steroid-like toxicity.
  • compositions of the present invention comprise, as an active ingredient, at least one compound acid of Formula I (see above), together with a pharmaceutically acceptable carrier.
  • the active ingredient is present in the composition in an amount sufficient to produce an
  • composition of the invention can be formulated so as to be suitable, for example, for oral, nasal, parenteral, topical, transdermal or rectal administration.
  • compositions can also be formulated so as to be suitable for veternary use.
  • Compounds (known and novel) that are preferred for use in the pharmaceutical composition of the present invention include those of Formula I wherein R 3 and R 4 are hydrogen, A and B are hydrogen or (C 1-4 ) alkyl, X is oxygen, and Q is a Iipophilic amino acid; compounds that are more preferred are those where A and B are alkyl; compounds that are the most preferred are those where A is a methyl group located in the 2 position of the fluorene ring and B is a methyl group located in the 7 position of the fluorene ring, and Q is leucine, isoleucine or nor-leucine.
  • the pharmaceutical composition of the invention includes the active ingredient of Formula I in a quantity selected from 25 mg to 500 mg, advantageously, from about 50 mg to 250 mg, per dosage unit, depending on the route of
  • compositions of the invention may be, for example, in solid or liquid form.
  • carrier carriers are lactose, magnesium stearate, terra alba, sucrose, talc, stearic acid, gelatin, agar, pectin or acacia.
  • the amount of solid carrier present in the composition will vary greatly but preferably will be from about 25 mg to 1 g.
  • liquid carriers are syrup, peanut oil, olive oil, sesame oil, propylene glycol,
  • the carrier or diluent may include a time delay material well known to the art such as, for example, glyceryl monostearate or glyceryl distearate alone or with a wax.
  • the pharmaceutical composition of the invention can be present in dosage unit form.
  • the composition can take the form of a tablet (preferrably enteric coated), capsule (preferrably enteric coated), powder, troche, lozenge, inhalant, syrup, emulsion, gel, ointment, cream, lotion transdermal patch, suppository, sterile injectable liquid as well as a liquid suspension or solution.
  • the pharmaceutical compositions of the present invention are prepared by conventional techniques such as by mixing, granulating and compressing or dissolving the ingredients as may be appropriate for the desired preparation.
  • the method of treating an inflammatory condition according to this invention comprises administering to a subject in need of such treatment an amount of at least one compound of Formula I (see above) sufficient to produce an anti-inflammatory effect.
  • the compounds of Formula I can be administered orally, nasally, topically,
  • the active ingredient of Formula I (see above) will normally be administered in a daily dosage regimen selected from about 100 mg to 1 g, most preferably from about 200 mg to about 500 mg.
  • equal doses will be administered, preferably, between one time per day to one time per week.
  • the frequency of administration and the amount of active ingredient to be administered to effect treatment of a particular inflammatory condition can readily be determined by one skilled in the art.
  • an aerosol dispensing system wherein the active medicament is incorporated with Freon ®
  • aerosol container fluorohydrocarbon or other inert propellant in an aerosol container is of particular applicability.
  • Such an aerosol system will deliver a metered dose of about 100 meg to about 650 meg, administered once or twice at a time as needed.
  • Phenylalanine (27.25 g, 0.165 mole) was dissolved in a solution of sodium carbonate (31.8 g, 0.3 mole) in 320 ml of water. This mixture was added to a solution of 9-fluorenylmethylsuccinimidyl carbonate (50.8 g, 0.15 mole) dissolved in a minimum amount of dioxane (approximately 90 ml being
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 1) were administered intraperitoneally (100 mg/kg) or topically as follows.
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 1) were administered intraperitoneally (100 mg/kg) or topically as follows.
  • test compound was dissolved in dimethyl sulfoxide or 0.5% methylcellulose and 100 ⁇ l was injected 30 minutes prior to irritant (100 mg/kg, i.p.).
  • test compound was dissolved in either acetone, ethanol or dimethyl sulfoxide and 5 ⁇ l (100 ⁇ g) applied to the upper surface (1 cm') of the ear and an additional 5 ⁇ l (100 ⁇ g) applied to the lower surface (1 cm 2 ) of the ear fifteen minutes prior to application of the irritant.
  • a solution of the irritant
  • tetradecanoylphorbolacetate 200 ⁇ g/ml was added to the surface of the ear, 5 ⁇ l added to the upper surface and 5 ⁇ l to the lower surface. After three hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. The results are reported in Table 1.
  • Formula I where X is oxygen, R 3 R 4 , A and B are hydrogen and Q is as indicated in Table 2) were administered intraperitoneally (100 mg/kg) as follows.
  • test compound was dissolved in DMSO or 0 . 5%
  • methylcellulose and 100 ⁇ l was injected 30 minutes prior to i.p. administration of 100 mg/kg of arachidonic acid.
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 3) were administered intraperitoneally (100 mg/kg) or topically as follows.
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 3) were administered intraperitoneally (100 mg/kg) or topically as follows.
  • test compound was dissolved in
  • test compound was dissolved in either acetone, ethanol or dimethyl sulfoxide and 5 ⁇ l (10 ⁇ g) applied to the upper surface (1 cm 2 ) of the ear and an additional 5 ⁇ l (10 ⁇ g) applied to the lower surface (1 cm 2 ) of the ear fifteen minutes prior to application of the irritant.
  • the irritant, xylene was added to the surface of the ear, 20 ⁇ l added to the upper surface and 20 ⁇ l to the lower surface. After two hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the midpoint of the pinna. Data were calculated as the inhibition by the test compound of increased ear thickness compared to that of control animals receiving only the irritant. The results are reported in Table 3.
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 4) were administered intraperitoneally (100 mg/kg) as follows.
  • the test compound was dissolved in DMSO or 0.5% methylcellulose and 100 ⁇ l was injected 30 minutes prior to irritant.
  • the irritant, capsaicin, 25 mg/ml was added to the ear, 5 ⁇ l added to the upper surface and 5 ⁇ l to the lower surface. After thirty minutes, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the
  • methylcellulose and 100 ⁇ l (100 mg/kg) was injected 30 minutes prior to irritant.
  • the irritant 3% oxazolone in acetone, was added to the surface of the ear, 5 ⁇ l added to the upper surface and 5 ⁇ l to the lower surface. After twenty four hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the
  • Test compounds (compounds of Formula I where X is oxygen, R 3 , R 4 , A and B are hydrogen and Q is as indicated in Table 6) were dissolved in dimethyl sulfoxide and 200 ⁇ l of this solution (100 mg/kg) were injected intraperitoneally one hour before administration of the antigen .
  • the animals were anesthetized inhalationally with isoflurane and then were injected through the penile vein with 1 ml of a solution of 2.5 mg of Evan's blue dye and 5.0 mg of human serum albumin in 1 ml of saline.
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine methyl ester NPC 15326)
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine ethyl ester NPC 15327)
  • N-[(9H-Fluoren-9-ylmothoxy)carbonyl]- L-leucine benzyl ester NPC 15328
  • N-[3-(9H-Fluoren-9-yl)propionyl]-L-leucine NPC 15476)
  • reaction was monitored by TLC (silica, 25% ethyl acetate in hexane).
  • the reaction mixture was stirred at room temperature for 3 hr. The excess of phosgene was removed by argon bubbling. The solvent was evaporated to afford a slightly yellow oil.
  • a solution of the oil in 5 mL of dioxane was charged with a solution of L-leucine (0.53 g, 4 mmol) in 14 mL of 10% aqueous solution of potassium carbonate and 7 mL of dioxane at room temperature.
  • the reaction mixture was stirred overnight and diluted with water (100 mL). The water layer was extracted with ethyl acetate (5x30 mL) then acidified to pH 2 with HCl.
  • N-[(9H-Fluoren-9-ylethoxy)carbonyl]- L-leucine N-[(9H-Fluoren-9-ylethoxy)carbonyl]- L-leucine (NPC 15521)
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine t-butyl ester NPC 15527
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl] L-leucine amide NPC 15528
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine methylamide NPC 15529
  • the reaction mixture was stirred for two days, diluted with 150 mL of water and extracted with ethyl acetate (5x25 mL). The water layer was acidified to pH 1. The precipitated oil was extracted with ethyl acetate (3x50 mL), the organic solutions were washed with 1N HCl (3x20 mL), water, brine, dried over magnesium sulfate and evaporated to give an oil which was solidified by stirring in an ether-hexane mixture. The compound was purified by a column chromatography on silica using a solution of
  • hydroxylammonium chloride (32.2 g, 464.0 mmol) in of water (108 mL) was charged with 6N sodium hydroxide (77 mL) at 5-10°C.
  • the resulting hydroxylamine solution was immediately added to the cupric sulfate solution.
  • the resulting solution at 5-10°C was charged with the diazonium solution at the same temperature during 40-50 min (the rate of addition is about 10 cc per minute) with a vigorous stirring. Stirring was continued for 5 min then heated to 70°C and acidified with conc. HCl. The mixture was allowed to stand overnight. The precipitate was filtered off, washed with water and dissolved in 400 mL of 10% sodium bicarbonate solution. This solution was treated with Norit, then filtered and acidified with 6N HCl. The precipitated product weighed 40.4 g (90.4 %).
  • reaction mixture was cooled down to 60°C, diluted with water (150 mL) then cooled down to room
  • the reaction mixture was stirred for 4 hr at room temperature. The excess of the phosgene was removed by bubbling argon. The solvents were removed under reduced pressure, the residue was dissolved in 10 mL of dioxane and the solution was added to a solution of L-leucine (1.71 g, 13.0 mmol) in 25.0 mL of dioxane and 49.0 mL of 10% potassium carbonate solution at room temperature. The reaction mixture was stirred overnight, the dioxane was removed under reduced pressure and the residue was diluted with 150 mL of water.
  • 1,3-dioxolane (9.0 g, 32 mmol) in 350ml acetone at 0°C was slowly charged with 350 mL of Jone's reagent (the reagent was made by dissolving 16 g of chromium trioxide and 64 mL of concentrated sulfuric acid in 400 mL of water).
  • the temperature raised to room temperature after all the reagent was added.
  • the reaction mixture was monitored by TLC (silica, 25% EtOAc in hexane). The reaction was completed within 5 hr.
  • the product was extracted with EtOAc and the organic layer was washed thoroughly with water (x6), until aqueous washings were clear and colorless.
  • N- ⁇ [9H-(1-Methoxymethylfluoren-9- yl)methoxy]carbonyl ⁇ -L-leucine NPC 15673
  • N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L- neopentylglycine quarter hydrate NPC 15676
  • N- ⁇ [9H-(1-Methylfluoren-9-yl)methoxy]carbonyl ⁇ -L- tert-leucine NPC 15952
  • N- ⁇ 9H-[3-(1-Methylfluoren-9-yl)propionyl] ⁇ - L-homophenylalanine NPC-1597
  • N- ⁇ 9H-[3-(4-Methylfluoren-9-yl)propionyl] ⁇ -L- leucine quarter hydrate NPC 15975
  • N- ⁇ 9H-[3-(1-MethyIfluoren-9-yl)propionyl] ⁇ - L-norleucine, quarter hydrate NPC 15976
  • the compound 3-(1-methylfluoren-9- yl) propionyl chloride (its preparation was described in Example 32; 4.0 g, 14.8 mmol) in 80 mL dioxane was charged with a solution of L-norleucine (4.0 g, 30.5 mmol) in 20 mL of 10% aqueous solution of sodium carbonate at room temperature. The reaction mixture was stirred for two hours. Most of the dioxane was removed under reduced pressure.
  • Test compounds were administered intraperitoneally or topically as follows. For intraperitoneal administration, the test compound v/as dissolved in dimethyl sulfoxide or 0.5% methylcellulose and 100 microliters was
  • micrograms applied to the upper surface and an additional 5 microliters applied to the lower surface of the ear fifteen minutes prior to
  • mice 25-30 g body weight, six
  • test compound was dissolved is dimethyl sulfoxide or 0.5% methylcellulose and 100 ⁇ L of the solution was injected intraperitoneally 30 minutes prior to the administration of 100 mg/kg of
  • arachidponic acid A solution of this irritant, 100 mg/mL in ethanol, was applied to the surface of the ear, 5 ⁇ L to the upper surface and 5 uL to the lower surface. After sixty minutes, the thickness of the ear was measured ot 0.01 mm by a micrometer with the loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the percent inhibityion by the test compound of increased ear thickness compared to control animals recieveing only the irritant. In general, %
  • CF-1 mice 25 -30 g body weight, six animals per group, were used.
  • the requisite amount of the test compound was dissolved is dimethyl sulfoxide or 0.5% methylcellulose and 100 ⁇ L of the solution was injected intraperitoneally 30 minutes prior to the administration the irritant.
  • the irritant xylene was applied to the surface of the ear, 20 ⁇ L to the upper surface and 20 ⁇ L to the lower surface. After two hours, the thickness of the ear was measured to 0.01 mm by a micrometer with the loose drag
  • mice 25-30 g body weight, five to six animals per group were used. The mice were
  • test compounds were administered
  • test compound was dissolved in dimethyl sulfoxide or 0.5%
  • irritant 3% oxazolone in acetone
  • 5 ⁇ L added to the upper surface
  • 5 ⁇ L added to the lower surface.
  • the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag, positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the inhibition of increased ear thickness compared to control animals' receiving only the irritant. In general, %
  • Adjuvant Arthritis Male Sprague Dawley rats, 150 - 200 g, were anesthetized with isoflurane. Drug was
  • the rat was then injected in the distal third of the tail with 0.5 mL of saline or 0.5 mL of well-sonicated Freund's complete adjuvant containing 1 mg/mL Mycobacterium
  • each rat was weighed and dosed with vehicle or drug suspension as before, but without anesthesia. On day 3, each rat was weighed and anesthetized. Blood was drawn by cardiac puncture into 0.2 mL of EDT ⁇ solution. Blood samples were microcentrifuged for 30 seconds. Then fibrinogen was converted into fibrin using sodium sulfite and the resulting fibrin was assayed using a Lowry protein assay to estimate initial fibrinogen levels.
  • Percent inhibition by test compound was determined by subtracting fibrinogen level in non-Freund's adjuvant-injected rats from fibrinogen levels in rats injected with adjuvant alone and those rats injected with adjuvant plus test compound, and dividing the resultant fibrinogen increases in drug treated animals by non-drug treated animals and multiplying by 100.
  • N-[9H-(2,3-Denzofluoren-9-ylmethoxy)carbonyl]-L-loucinc NPC 15510
  • N-((9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucino amide NPC 15528

Abstract

The present invention relates to a method of treating an inflammatory condition, and to compounds and composition suitable for use in such a method, which compounds have formula (I) wherein: X is methylene, ethylene, ethyleneoxy, or oxygen; Q is (a) where C' is a residue of a lipophilic amino acid, and Y is -CO2H, -CH2OH, -CONR1R2, or -CO2R1 where R1 and R2 are hydrogen, alkyl, or aryl; R3 and R4 are, independently, hydrogen, alkyl or aryl; and A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro; or pharmaceutically acceptable salts thereof.

Description

METHODS FOR TREATING INFLAMMATION
AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN
This application is a continuation-in- part of application Serial No. 07/369,710, filed June 22, 1989.
Background of the Invention Technical Field
This invention relates to methods for treating inflammatory conditions and to compounds and pharmaceutical compositions suitable for
therein.
Background Information
The treatment of inflammatory conditions, such as atopic dermatitis, contact dermatitis, psoriasis, rheumatoid arthritis, glomerulonephritis, osteoarthritis, lupus erythematosis, scleroderma, asthma and irritable bowel disease has, in the past, involved the use of agents such as aspirin-like nonsteroidal anti-inflammatory agents,
glucocorticoids, methotrexate and cyclophosphamide. Unfortunately these agents generally produce
unv/αnted side effects. Specifically, the
nonsteroidal anti-inflammatory drugs often cause gastrointestinal and renal side effects.
Glucocorticoids suppress the immune system, thus producing opportunistic infection and
endocrinopathy. Methotrexate has been associated with patient death, and cyclophosphamide has
carcinogenic liability. Thus, new agents for treating inflammatory conditions that are free of these adverse side effects are needed.
Objects of the Invention
It is a general object of the present invention to provide a method of treating a subject suffering from an inflammatory condition while avoiding the adverse side effects associated with art-recognized anti-inflammatory agents. It is a further object of the invention to provide compounds and pharmaceutical compositions suitable for use in such a method.
Further objects and advantages of the invention will be clear to one skilled in the art from a reading of the description that follows.
Summary of the Invention The present invention relates to a method of treating a subject having an inflammatory
condition, such as atopic or contact dermatitis, psoriasis, rheumatoid arthritis, glomerulonephritis, osteoarthritis, lupus erythemαtosis, scleroderoma, asthma or irritable bowel disease. The invention also relates to compounds and pharmaceutical
compositions suitable for use in such a method.
In one embodiment, the present invention relates to a method of treating an inflammatory condition comprising administering to an animal in need of such treatment at least one compound of Formula I:
I
Figure imgf000004_0001
wherein:
X is methylene, ethylene, ethyleneoxy, or oxygen;
Q is p wherein C' is a residue of a
Figure imgf000005_0001
Iipophilic amino acid and Y is -CO2H, -CH2OH,
-CONR1R2, or -CO2R1 where R1 and R7 are hydrogen, alkyl, or aryl;
R3 and R4 are, independently, hydrogen, alkyl or aryl; and
A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro;
or a pharmaceutically acceptable salt thereof, in an amount sufficient to reduce or eliminate the inflammatory condition.
In a further embodiment, the present invention relates to a pharmaceutical composition comprising the compound of Formula I (above) in an amount sufficient to produce an anti-inflammatory effect, together with a pharmaceutically acceptable carrier.
In another embodiment, the present invention relates, generally, to compounds of
Formula I wherein X, Q, R3, R4 , A and B are defined as set forth above, providing that when R3 , R4, A and B are hydrogen and Y is -C07H (or salt thereof), X is not oxygen, and further providing that when A or B are, independently, hydrogen or halogen, R3 and R4 are hydrogen, X is oxygen, and Y is -CO2H (or salt thereof), C' is not an aromatic amino acid residue. The invention does, however, include N-[9H-(fluoren- 9-ylmethoxy)carbonyl]-L-tert-leucine and N-[(9H- fluoren-9-ylmethoxy)carbonyl]-L-neopentylglycine. Detailed Description of the Invention
Compounds that are suitable for use in the method of treating an inflammatory condition of the present invention, are represented by the following Formula I:
I
Figure imgf000006_0002
wherein:
X is methylene, ethylene, ethyleneoxy, or oxygen;
Q is where C' is a residue of a
Figure imgf000006_0001
Iipophilic amino acid, and Y is -CO2H, -CH2OH,
-CONR1R2, or -CO2R, wherein R1 and R3 are hydrogen, alkyl (advantageously, C1-4) or aryl (advantageously, C6-12);
R3 and R4 are, independently, hydrogen, alkyl (advantageously, C1-4) or aryl (advantageously, C6-12); and
A and B are, independently, hydrogen, fused phenol, alkyl (advantageously, C1-9), aryl (advantageously, C6-12), alkaryl (advantageously, (C1-9)alk(C6-12)aryl), aralkyl (advantageously,
(C6-12)ar(C1-9)alkyl), alkoxy (advantageously, C1-9), alkoxyalkyl (advantageously (C1-9)alkoxy(C1-9)alkyl), halogen or nitro.
The above-named hydrocarbons can be unsubstituted or substituted with a C1-4 alkyl group. The term Iipophilic amino acid as used herein includes within its scope amino acids, the residues of which do not contain free hydroxy groups, free thiol groups, or basic nitrogen atoms.
Pharmaceutically acceptable salts of the above-described compounds can be used in the
compositions and methods to which the invention relates.
Certain of the compounds of Formula I described above are known in the art [see
specifically compounds disclosed in United States Patents 3,835,175 and 3,906,031 (see also
4,394,519)]. The remaining compounds are believed to be disclosed for the first time herein. The use of these agents (known and novel) in the treatment of inflammation has not been previously described.
Of the known compounds of Formula I, one that is preferred for use in the present method is the compound N-[(9H-fluoren-9-ylmethoxy)carbonyl]- L-leucine. In addition, N-[(9H-fluoren-9- ylmethoxy)carbonyl]-L-norleucine, and S-benzyl-β,β- dimethyl-N-[9H-(fluoren-9-ylmethoxy)carbonyl]-D- cystein, are also known compounds that are preferred for use in the present method.
The novel compounds of Formula I that are preferred for use in the present method are those wherein: i) R3, R4, A and B are hydrogen, X is methylene, and Q is a Iipophilic amino acid; and ii) R3 and R4 are hydrogen, X is oxygen, A and/or B each represents at least one alkyl substituent, and Q is a Iipophilic amino acid. The novel compounds of Formula I that are the most preferred for use in the present method are those wherein: i) R3 and R4 are hydrogen, X is oxygen, A is a methyl group located in the 4 position of the fluorene ring, B is
hydrogen, and Q is the amino acid leucine; ii) R3 and R4 are hydrogen, X is oxygen, A is a methyl group located in the 4 position of the fluorene ring, B is hydrogen, and Q is the amino acid homophenylalanine; and iii) R3 and R4 are hydrogen, X is oxygen, A is a methyl group located in position 2 of the fluorene ring, B is a methyl group located in position 7 of the fluorene ring, and Q is the amino acid leucine.
The above compounds of Formula I can be prepared by methods known in the art (see also
Examples below). For example, details of synthetic procedures suitable for use in preparing N-[9H- fluoren-9-ylmethoxy)carbonyl]-amino acids have been described by L.A. Carpino and G.Y. Han (U.S. Patents 3,835,175 and 3,906,031) (see also Examples below). Typically, a 9H-fluorene is utilized as the starting material. This is converted to a corresponding 9H- fluoren-9-ylmethanol, for example, by condensation of a 9H-fluorene with methyl formate in the presence of sodium ethoxide, followed by reduction of the intermediate 9H-fluorene-9carboxaldehyde.
Alternatively, 9H-fluorene can be condensed directly with formaldehyde in the presence of a strong base such as sodium hydride or sodium amide to give the 9-methanol derivative. Compounds in which the alpha carbon atom is substituted may be prepared by reaction between the selected 9H-fluorene and an aldehyde other than formaldehyde or a ketone, such as acetone or acetophenone, in the presence of a strong base.
Introduction of substituents in the benzo fused rings of the 9H-fluorene can be achieved by known procedures as, for example, by direct
halogenation or nitration.
9H-Fluoren-9-ylmethanols are converted to 9H-fluoren-9-ylmethanol haloformates, carbonates, thiocarbonates, imidylcarbonates or other formate derivatives bearing a grouping ("leaving group") that is readily displaced by a nucleophilic nitrogen of an alpha amino acid. The resulting carbonyl derivatives of an activated 9H-fluoren-9-ylmethanol are condensed with an alpha aminocarboxylic acid to form a 9H-fluoren-9-ylmethoxycarbonyl derivative of the general Formula I. If the "leaving group" is halogen, especially chlorine, reaction may be effected in a polar organic solvent such as dioxane, tetrahydrofuran, dimethylformamide or pyridine under alkaline conditions (preferably mild) at a low temperature, for example from 0°C to 25°C during a period of from about 2 to 3 hours. A preferred solvent is a mixture of dioxane and water.
Normally, the N-[(9H-fluoren-9-ylmethoxy)carbonyl]- amino acid precipitates from solution and may be purified, for example, by recrystallization.
Utilization of other "leaving groups" may require somewhat elevated temperatures, for example, 25°C to 50°C and longer reaction times, for example, 8 to 12 hours.
The Examples below include further
synthetic schemes for preparing the novel compounds to which the present invention relates.
The compounds of Formula I, where possible, are advantageously utilized as the free acid or in the form of a pharmaceutically acceptable salt with various inorganic or organic bases.
Typical salts include the alkali metal or alkaline earth salts, although it will be appreciated that other nontoxic salts can also be used.
Advantageously, compounds suitable for use in the present method this invention are administered as sodium, potassium, ammonium, choline or
ethylenediamine salts. Sodium salts are preferred. As will be understood by those skilled in the art, the compounds of this invention can be present as D or L optical isomers or, in some cases, as
diastereoisomers as well as racemates and diastereoisomeric mixtures. Unless otherwise
specified, the compounds of Formula I include all isomers of such compounds, whether separated or mixtures thereof.
The activity of a compound of Formula I as an anti-inflammatory agent can be demonstrated in animals, such as mice, for example, by measuring the ability of the compound to inhibit edema caused by a variety of inflammatory agents that are generally accepted as producing irritation by differing mechanisms. Such inflammatory agents typically include tetradecanoylphorbolacetate, arachidonic acid, xylene, capsaicin, oxazolone, carrageenan and the like. The reverse passive Arthus test offers another measure of the compound's utility in
preventing an inflammatory response (Chang et al, Eur. J. Pharm. 69:155-164 (1981)). Test compounds are typically administered intraperitoneally or topically. For intraperitoneal administration, the test compound can be given in dimethyl sulfoxide or in 0.5% methylcellulose 30 minutes prior to
administration of the irritant. For topical
administration, the test compound can be dissolved in, for example, acetone, ethanol or dimethyl sulfoxide and applied about 15 minutes prior to application of the irritant. Results can be
expressed as the percent decrease in swelling in the compound-treated animals as compared to control animals that receive only the irritant.
It is noteworthy that currently available non-steroidal anti-inflammatory agents operate by a single mechanism (cyclo-oxygenase inhibitors), thus, they are highly active in a single assay (steroids are usually active in most, if not all, screens but have side effects that prohibit their widespread use). The compounds of Formula I are highly active in almost all of the inflammatory screens and are also highly active in the reverse passive artus assay and in adjuvant arthritis, which are
considered to be predictive of activity against human arthritis. That is, the compounds of Formula I have the steroid-like spectrum of activity but lack steroid-like toxicity.
The pharmaceutical compositions of the present invention comprise, as an active ingredient, at least one compound acid of Formula I (see above), together with a pharmaceutically acceptable carrier. The active ingredient is present in the composition in an amount sufficient to produce an
anti-inflammatory effect. The composition of the invention can be formulated so as to be suitable, for example, for oral, nasal, parenteral, topical, transdermal or rectal administration. (The
compositions can also be formulated so as to be suitable for veternary use.)
Compounds (known and novel) that are preferred for use in the pharmaceutical composition of the present invention include those of Formula I wherein R3 and R4 are hydrogen, A and B are hydrogen or (C1-4) alkyl, X is oxygen, and Q is a Iipophilic amino acid; compounds that are more preferred are those where A and B are alkyl; compounds that are the most preferred are those where A is a methyl group located in the 2 position of the fluorene ring and B is a methyl group located in the 7 position of the fluorene ring, and Q is leucine, isoleucine or nor-leucine.
Preferably, the pharmaceutical composition of the invention includes the active ingredient of Formula I in a quantity selected from 25 mg to 500 mg, advantageously, from about 50 mg to 250 mg, per dosage unit, depending on the route of
administration. Appropriate concentrations and dosage unit sizes can be readily determined by one skilled in the art.
The pharmaceutical carriers used in the compositions of the invention may be, for example, in solid or liquid form. Exemplary of solid
carriers are lactose, magnesium stearate, terra alba, sucrose, talc, stearic acid, gelatin, agar, pectin or acacia. The amount of solid carrier present in the composition will vary greatly but preferably will be from about 25 mg to 1 g.
Exemplary of liquid carriers are syrup, peanut oil, olive oil, sesame oil, propylene glycol,
polyethylene glycol (mol. wt. 200-400) and water. The carrier or diluent may include a time delay material well known to the art such as, for example, glyceryl monostearate or glyceryl distearate alone or with a wax.
As indicated above, the pharmaceutical composition of the invention can be present in dosage unit form. For example, the composition can take the form of a tablet (preferrably enteric coated), capsule (preferrably enteric coated), powder, troche, lozenge, inhalant, syrup, emulsion, gel, ointment, cream, lotion transdermal patch, suppository, sterile injectable liquid as well as a liquid suspension or solution. The pharmaceutical compositions of the present invention are prepared by conventional techniques such as by mixing, granulating and compressing or dissolving the ingredients as may be appropriate for the desired preparation.
The method of treating an inflammatory condition according to this invention comprises administering to a subject in need of such treatment an amount of at least one compound of Formula I (see above) sufficient to produce an anti-inflammatory effect. The compounds of Formula I can be administered orally, nasally, topically,
transdermally, parenterally or anally, as may be required to effect the desired anti-inflammatory effect.
The active ingredient of Formula I (see above) will normally be administered in a daily dosage regimen selected from about 100 mg to 1 g, most preferably from about 200 mg to about 500 mg.
Advantageously, equal doses will be administered, preferably, between one time per day to one time per week. The frequency of administration and the amount of active ingredient to be administered to effect treatment of a particular inflammatory condition can readily be determined by one skilled in the art. For inflammatory conditions of the lungs, an aerosol dispensing system wherein the active medicament is incorporated with Freon®
(fluorohydrocarbon) or other inert propellant in an aerosol container is of particular applicability. Such an aerosol system will deliver a metered dose of about 100 meg to about 650 meg, administered once or twice at a time as needed.
The following non-limiting Examples, which are illustrative of the compounds suitable for use in the methods and compositions of the present invention, demonstrate the activity of these compounds as well as processes for their
preparation. EXAMPLE 1
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-phenylalanine
9H-Fluoren-9-ylmethylchloroformate (51.4 g, 0.143 mole) and N-hydroxysuccinimide (29.0 g, 0.252 mole) were dissolved in 350 ml of dry, distilled dioxane. The mixture was cooled in ice and 27.9 ml of triethylamine was added slowly, so as to maintain the temperature of the mixture below 10°C. After four hours, the mixture was filtered to remove triethylammonium chloride. The solid was well washed with dioxane and the combined filtrates concentrated under reduced pressure. The product,
9-fluorenylmethyl-succinimidyl carbonate, 74 g, was crystallized by addition of petroleum ether and cooling to 4°C.
Phenylalanine (27.25 g, 0.165 mole) was dissolved in a solution of sodium carbonate (31.8 g, 0.3 mole) in 320 ml of water. This mixture was added to a solution of 9-fluorenylmethylsuccinimidyl carbonate (50.8 g, 0.15 mole) dissolved in a minimum amount of dioxane (approximately 90 ml being
required). The mixture was stirred vigorously
(mechanical stirring) at room temperature for 22 hours and then diluted with water. The reaction mixture was extracted twice with ethyl ether and then acidified to pH 2 with concentrated
hydrochloric acid in the presence of 750 ml of ethyl acetate. The organic layer was separated, washed twice with 1 N hydrochloric acid, twice with water, once with brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was crystallized by addition of hexane to the boiling ethyl acetate solution, to give 18 g of N-[(9H-fluoren-9ylmethyloxy)carbonyl]-L- phenylalanine, mp 179-181°C.
EXAMPLE 2
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine To a solution of (1.31 g, 10 mmole) of
L-leucine in 27 ml of water was added (2.5 g, 23 mmole) of sodium carbonate and the mixture was cooled in ice. To this was added a solution of
(2.58 g, 7.2 mmole) of 9-fluorenylmethyl
chloroformate in 20 ml of dioxane. The mixture was stirred at room temperature for 2.5 hours and diluted with 500 ml of water. The reaction mixture was extracted twice with ethyl ether. The aqueous layer was made acidic to Congo Red indicator paper with concentrated hydrochloric acid and the
precipitate collected by filtration. The solid was recrystallized from ethyl acetate to give 0.9 g of
N-[(9H-fluoren-9-ylmethyloxy)carbonyl)]-L-leucine, mp 151-155°C.
EXAMPLE 3
Inhibition of Ear Edema Caused by Tetradecanoylphorbolacetate (I)
CF-1 Mice, 25-30 g body weight, six animals per group, were used. Test compounds (compounds of Formula I where X is oxygen, R3, R4, A and B are hydrogen and Q is as indicated in Table 1) were administered intraperitoneally (100 mg/kg) or topically as follows. For intraperitoneal
administration, the test compound was dissolved in dimethyl sulfoxide or 0.5% methylcellulose and 100 μl was injected 30 minutes prior to irritant (100 mg/kg, i.p.). For topical administration, the test compound was dissolved in either acetone, ethanol or dimethyl sulfoxide and 5 μl (100 μg) applied to the upper surface (1 cm') of the ear and an additional 5 μl (100 μg) applied to the lower surface (1 cm2) of the ear fifteen minutes prior to application of the irritant. A solution of the irritant,
tetradecanoylphorbolacetate, 200 μg/ml, was added to the surface of the ear, 5 μl added to the upper surface and 5 μl to the lower surface. After three hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. The results are reported in Table 1.
Figure imgf000016_0001
EXAMPLE 4
Inhibition of Ear Edema Caused by
Arachidonic Acid (I)
CF-1 Mice, 25-30 g body weight, six animals per group, were used. Test compounds (compounds of
Formula I where X is oxygen, R3 R4, A and B are hydrogen and Q is as indicated in Table 2) were administered intraperitoneally (100 mg/kg) as follows. For intraperitoneal administration, test compound was dissolved in DMSO or 0 . 5%
methylcellulose and 100 μl was injected 30 minutes prior to i.p. administration of 100 mg/kg of arachidonic acid. A solution of the irritant, arachidonic acid, 100 mg/ml in ethanol, was added to the surface of the ear, 5 μl added to the upper surface and 5 μl to the lower surface. After sixty minutes, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the percent
inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. The results are reported in Table 2.
Figure imgf000018_0001
EXAMPLE 5
Inhibiton of Ear Edema Caused by Xylene (I)
CF-1 Mice, 25-30 g body weight, six animals per group, were used. Test compounds (compounds of Formula I where X is oxygen, R3, R4, A and B are hydrogen and Q is as indicated in Table 3) were administered intraperitoneally (100 mg/kg) or topically as follows. For intraperitoneal
administration, the test compound was dissolved in
DMSO or 0.5% methylcellulose and 100 μl was injected 30 minutes prior to irritant. For topical
administration, test compound was dissolved in either acetone, ethanol or dimethyl sulfoxide and 5 μl (10 μg) applied to the upper surface (1 cm2) of the ear and an additional 5 μl (10 μg) applied to the lower surface (1 cm2) of the ear fifteen minutes prior to application of the irritant. The irritant, xylene, was added to the surface of the ear, 20 μl added to the upper surface and 20 μl to the lower surface. After two hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the midpoint of the pinna. Data were calculated as the inhibition by the test compound of increased ear thickness compared to that of control animals receiving only the irritant. The results are reported in Table 3.
Figure imgf000019_0001
EXAMPLE 6
Inhibition of Ear Edema Caused by Capsaicin CF-1 Mice , 25-30 g body weight, six animals per group, were used. Test compounds (compounds of Formula I where X is oxygen, R3, R4, A and B are hydrogen and Q is as indicated in Table 4) were administered intraperitoneally (100 mg/kg) as follows. The test compound was dissolved in DMSO or 0.5% methylcellulose and 100 μl was injected 30 minutes prior to irritant. The irritant, capsaicin, 25 mg/ml, was added to the ear, 5 μl added to the upper surface and 5 μl to the lower surface. After thirty minutes, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the
inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. The results are reported in Table 4.
Figure imgf000020_0001
EXAMPLE 7
Inhibition of Ear Edema Caused by Oxazolone (I) CF-1 Mice, 25-30 g body weight, six animals per group, were used. The mice were sensitized to the irritant two weeks prior to the test by dribbling 100 μl of a 3% solution of oxazolone in acetone onto the abdominal skin of the animal. Test compounds (compounds of Formula I where X is oxygen, R3, R4, A and B are hydrogen and Q is as indicated in Table 5) were administered intraperitoneally as follows. The test compound was dissolved in DMSO or 0.5%
methylcellulose and 100 μl (100 mg/kg) was injected 30 minutes prior to irritant. The irritant, 3% oxazolone in acetone, was added to the surface of the ear, 5 μl added to the upper surface and 5 μl to the lower surface. After twenty four hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag positioned at the
lateral-most edge of the mid-point of the pinna. Data were calculated as the inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. The results are reported in Table 5.
Figure imgf000022_0001
EXAMPLE 8
Reverse Passive Artus Reaction (I)
Male CD rats weighing between 200 and 250 g were used. Test compounds (compounds of Formula I where X is oxygen, R3 , R4 , A and B are hydrogen and Q is as indicated in Table 6) were dissolved in dimethyl sulfoxide and 200 μl of this solution (100 mg/kg) were injected intraperitoneally one hour before administration of the antigen . The animals were anesthetized inhalationally with isoflurane and then were injected through the penile vein with 1 ml of a solution of 2.5 mg of Evan's blue dye and 5.0 mg of human serum albumin in 1 ml of saline. This treatment was followed immediately by intracutaneous injections of 0.03 ml of anti-human albumin diluted to contain 3.65 mg of antibody at 3 sites along the midline back. Anesthesia was terminated and after three hours the animals were sacrificed. The skin was removed and the blue stained areas cut out. The skin patches were soaked overnight in stoppered tubes containing 1 ml of 1 N potassium hydroxide at 37°C. Then 9 ml of a mixture of five parts of 0.6 N phosphoric acid and thirteen parts of acetone was added to the tubes. The tube contents were agitated and centrifuged, and the absorbance of the
supernatant liquid was measured at 620 nm. The data were calculated as inhibition of blueing by test compound compared to control animals receiving only antigen and antibody. The results are reported in Table 6.
Figure imgf000023_0001
EXAMPLE 9
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N- methyl-L-leucine (MPC 15273)
A suspension of N-[(9H-fluoren-9- ylmethoxy)carbonyl]-L-leucine (1.67 g, 5 mmol) in toluene (100 ml) was charged with paraformaldehyde
(1 g, 33.3 mmol) and 4-toluenesulfonic acid (100 mg, catalytic). The mixture was refluxed for 30 minutes in a Dean Stark apparatus for azeotropic
distillation. The solution was washed with a saturated solution of sodium bicarbonate (x2), dried over magnesium sulfate and evaporated. The
resulting oil in a 1:1 mixture of
chloroform:trifluoroacetic acid (50 ml), at room temperature, was charged with triethylsilane (2.38 ml, 15 mmol). Stirring was continued for 22 hr.
The solvents were removed in vacuum and the oil was crystallized from a mixture of ether:hexane.
Recrystalyzation from EtOAc:hexane afforded 0.85 g (46%) of the product as a colorless solid, mp 101- 3°C. EXAMPLE 10
N-{[9H-(4-MethyIfluoren-9-yl)methoxy]carbonyl}- L-leucine (NPC 15325) 9-Hydroxyfluorene-4-methanol
A solution of 9-fluorenone-4-carboxylic acid (14.8 g, 66 mmol) in 250 mL of THF, at 0°C was charged with a solution of 1M borane-THF complex in THF (150 mL, 150 mmol). The temperature was slowly elevated to room temperature. After 1.5 hr at room temperature the reaction was quenched with water. The reaction mixture was diluted with EtOAc. The organic layer was washed with water (x3), dried over magnesium sulfate and evaporated. Recrystallization from ether with traces of EtOAc afforded 12.4 g (88.5%) of the diol. 4-Methylfluorene
A solution of 9-hydroxyfluoren-4-methanol (2.6 g, 12.2 mmol) in 1:1 EtOAc:AcOH was charged with catalytic amount of 10% palladium on charcoal. The mixture was treated with hydrogen under 1600 psi, at room temperature for three days. The catalyst was removed and the solvent was evaporated under reduced pressure. Recrystalyzation from MeOH afforded 1.7 g (77.0%) of the product as a light yellow solid.
4-Methyl-9-fluorenecarboxylic acid
A solution of 4-methylfluorene (4.15 g, 23.0 mmol) in 120 mL THF at -78°C was charged with a solution of 2.45 M BuLi in hexane (9.9 mL, 24.2 mmol). The color of the solution turned dark red and precipitation was apparent. After 45 minutes at -78°C the reaction mixture was introduced with carbon dioxide gas (excess). The color soon disappeared and after 30 minutes at -78°C the reaction mixture was warmed to room temperature. The reaction mixture was diluted with ether and ethyl acetate and the carboxylic salt was extracted with water twice. The combined aqueous phase was washed with ether then acidified with dilute HCl. The resulting solid was filtered, redissolved in ethyl acetate, dried with magnesium sulfate and evaporated. The resulting solid 3.15 g (61.1%) was carried on to the next step without further
purification. 4-Methyl-9-fluorenemethanol
A solution of 4-methyl-9- fluorenecarboxylic acid (3.1 g, 13.8 mmol) in 90 mL of THF at 0°C, was charged with a solution of borane-THF (1M in THF, 27.6 mL, 27.6 mmol). The temperature was slowly elevated and the reaction mixture was stirred at room temperature overnight. The reaction was quenched with water, diluted with EtOAc, washed with water (x3), dried over magnesium sulfate and evaporated. The crude compound 2.8 g (96.5%) was pure enough to be carried as is to the next step.
4-MethyIfluorenyl-9-methoxycarbonyl-L-leucine
A solution of 4-methyl-9-fluorenemethanol
(2.5 g, 11.9 mmol) in 20 mL of toluene, at 0°C was charged with a solution of phosgene (20% in toluene, 12 g, 24 mmol). After 24 hours at room temperature additional excess of phosgene was introduced. After additional 2 hr at 50°C and 2 hr at 90°C in a sealed tube the reaction was stopped. The reaction was evaporated to dryness. The crude oil was dissolved in 20 mL dioxane then was added to a 40 mL
suspension of L-leucine (3.12 g, 23.8 mmol) in 10% aqueous sodium carbonate. Additional dioxane was added in order to turn the slurry into an
homogeneous solution. The reaction was completed within 15 minutes at room temperature. Part of the dioxane was evaporated in vacuum and the mixture was diluted with water. The aqueous phase was washed with ether (x3) then acidified with dilute HCl. The resulting product was purified on silica with 10% MeOH in chloroform. Further purification on a reverse phase silica (RP-18, from 1:1 to 4:6
MeOH:water) afforded 900 mg (20.6%) of the product as a colorless solid, mp 120-2°C. EXAMPLE 11
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine methyl ester (NPC 15326)
A suspension of L-leucine methyl ester hydrochloride (3.0 g, 16.5 mmol) and sodium
bicarbonate (large excess) in 30 mL of dioxane was charged with 9-fluorenemethoxycarbonyl-O-succinimide (2.5 g, 7.43 mmol) at room temperature. The reaction was monitored via TLC (silica, 25% EtOAc in hexane). After two hours 30 ml of methylene chloride was introduced and the reaction was stirred at room temperature for 48 hours. The solution was diluted with EtOAc, washed with water (x2), 3% aqueous HCl, water (x3) and brine. The solution was dried over magnesium sulfate and evaporated. The resulting oil was crystalized from hexane:ether to yield 1.9 g (62%) of colorless solid.
EXAMPLE 12
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine ethyl ester (NPC 15327)
The reaction was carried out upon treating L-leucine ethyl ester hydrochloride with 9- fluorenemethoxycarbonyl-O-succinimide via the same procedure as described for Example 11: N-[(9H- fluoren-9-ylmethoxy)carbonyl]-L-leucine methyl ester, and yielded 54.4%; mp 86-7°C. EXAMPLE 13
N-[(9H-Fluoren-9-ylmothoxy)carbonyl]- L-leucine benzyl ester (NPC 15328)
A solution of L-leucine benzyl ester tosylate (5.8 g, 14.8 mmol) in 80 mL methylene chloride was stirred together with aqueous solution of saturated sodium bicarbonate (large excess) for 15 min at room temperature. The organic phase was separated, dried over magnesium sulfate and charged with 9-fluorenemethoxycarbonyl-O-succinimide (2.5 g, 7.4 mmol) at room temperature. The reaction was monitored via TLC (silica, 25% EtOAc in hexane). After two hours the reaction was over (according to its TLC with 25% EtOAc in hexane). However it was further stirred at room temperature for 48 hours. The solution was diluted with EtOAc then was washed with water (x2), 3% aqueous HCl, water (x3) and brine. The solution was dried over magnesium sulfate and evaporated. The resulting oil was crystallized from hexane:ether to yield 2.2 g
(48.7%) of colorless solid, mp 91-2°C. EXAMPLE 14
2-{N-[(9H-Fluoren-9-ylmethoxy)carbonyl] amino}-4-methylpentanol (NPC 15427) A solution of F-MOC-L-leucine (8 g, 22.6 mmol) in THF (22 ml), at 0°C, was charged with borane-THF complex(1M solution in THF, 45.3 mL, 45.3 mmol). After three hours of stirring at 0°C, the reaction mixture was quenched with 10% solution of AcOH in MeOH. The solvents were removed in vacuum and the residual oil was dissolved in EtOAc (100 mL). The organic solution was washed with 1N HCl, water (x2) and a saturated solution of sodium bicarbonate, dried over magnesium sulfate and evaporated. The residual oil was stirred for 48 hours in hexane.
The precipitate was collected and recrystallized from EtOAc:hexane to yield 3.7 g (48.2%) of 2-[N- (9-fluorenylmethoxycarbonyl)amino]-4-methylpentanol as colorless solid, mp 131-3°C.
EXAMPLE 15 N-[9H-Fluoren-9-ylmethoκy)carbonyl]-L-leucine
1-glyceryl ester (NPC 15430)
A solution of N-[9H-fluoren-9- ylmethoxy)carbonyl]-L-leucine (5 g, 14.1 mmol) and solketal (3.7 g, 28.3 mmol) in methylene chloride (50 mL) was charged with dicyclohexylcarbodiimide (3.65 g, 17.7 mmol). After 10 minutes the reaction was completed (upon monitoring with TLC on silica with 25% EtOAc in hexane). The solid was filtered off and the solvent was removed in vacuum. The crude product was then treated with HCl in acetone (70 mL) for 48 hr. The solvent was removed in vacuum and the crude product was dissolved in EtOAc. The organic solvent was washed with water (x3) dried over magnesium sulfate and evaporated. The
resulting oil was purified on a column
chromatography using from 50% to 70% EtOAc in
hexane. Crystallization took place upon triturating the resulting oil in pentane to produce colorless solid 2.86 g (23.6%), mp 78-83°C.
EXAMPLE 16
N-[3-(9H-Fluoren-9-yl)propionyl]-L-leucine (NPC 15476)
9-(2-Ethyl-1,3-dioxolane-2-yl)fluorene
A solution of BuLi (2.35 M in hexane, 25.6 mL, 60.2 mmol) was slowly added into a cooled (-78°C) solution of fluorene (10 g, 60.2 mmol) in 200 mL THF. The reaction mixture turned dark red and solid started to precipitate out. After 30 minutes 2-(2-bromoethyl)-1,3-dioxolane (12 g, 66.3 mmol) was added to the cold solution and the
solution was warmed up to room temperature. TLC (silica, 5% EtOAc in hexane) was used to monitor the reaction. After two hours the reaction was quenched with water and the product was extracted into EtOAc. The organic layer was washed with water (x3), dried over magnesium sulfate and evaporated. Short path chromatography afforded 8.34 g (52%) of the product as a colorless oil. 3-(Fluoren-9-yl)propionic acid
A solution of 9-[2-(-2-ethyl-1,3- dioxolane)]-fluorene (8.3 g, mmol) in 350 mL acetone at 0°C was slowly charged with 350 mL of Jone's reagent (the reagent was made by dissolving 16 g of chromium trioxide and 64 mL of concentrated sulfuric acid in 400 mL of water). A very strong reaction was observed during the addition of the oxidant. The temperature was raised to room temperature after all the reagent was added. The reaction mixture was monitored by TLC (silica, 25% EtOAc in hexane). The reaction was completed within 5 hr. The product was extracted with EtOAc and the organic layer was washed thoroughly with water (x6) until aqueous washings were clear and colorless. Recrystalyzation from MeOH:water afforded 6.5 g (87.5%).
N-[3-(9H-Fluoren-9-ylpropionyl)]-L-leucine t-butyl ester
A solution of 3-(fluoren-9-yl)propionic acid (3.0 g, 12.6 mmol) and leucine t-butyl ester
(2.59 g, 13.8 mmol) in methylene chloride at room temperature (60 mL) was charged with 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (2.65 g, 13.8 mmol). After two hours at room temperature TLC (silica, 25% EtOAc in hexane) indicated the completion of the reaction. The methylene chloride was removed in vacuum and EtOAc was introduced. The organic solvent was washed with water (x2), 10% aqueous potassium carbonate and water again, dried over magnesium sulfate and evaporated. The resulting oil was filtered through a short column of silica with 25% EtOAc in hexane. The yield after evaporation was 4.25 g (82.8%).
N-[3-(9H-Fluoren-9-ylpropionyl)]-L-leucine
A solution of N-[3-(9H-fluoren-9- ylpropionyl)]-L-leucine t-butyl ester (4.2 g, 10.3 mmol) in 1:1 trifluoroacetic acid:methylene chloride was stirred overnight at room temperature. The solvents were removed in vacuum and the resulting oil was recrystallized from EtOAc: hexane to
afforded 1.5 g (41.2%), mp 143-5°C.
EXAMPLE 17
N-{[9H-(2-MethyIfluoren-9-yl)methoxy]carbonyl}-L- leucine (NPC 15477)
2-MethyIfluorene
A solution of 2-fluorenecarboxaldehyde (15 g, 77.1 mmol) in 250 mL of 10% solution of acetic acid in ethyl acetate was hydrogenated at 80 psi of hydrogen during 24 hours at room temperature over 20% palladium hydroxide on carbon (catalytic
amount). The reaction was monitored by TLC (silica, 25% ethyl acetate in hexane). The catalyst was filtered off, evaporation of the solvents followed by recrystallization of the residual solid from ethanol:water 5:1 afforded 9.6 g (69.0%) of the product as colorless solid. 2-Methyl-9-fluorenecarboxylie acid
A solution of 2-methylfluorene (6 g, 33.2 mmol) in 100 ml of THF at -78°C was charged with butyl lithium (2.18 g, 34.0 mmol). The reaction mixture was stirred for 15 min then CO2 gaseous (5 g, 113.6 mmol) was introduced via a cannula over a period of 15 min at -78°C. The reaction mixture was warmed up to room temperature and stirred for additional 2 hr until colorless. The reaction mixture was diluted with 250 mL of water and 100 mL of ethyl acetate, the layers were separated, the aqueous phase was washed with ethyl acetate (3 x 50 mL) and acidified to pH 2 with cone. HCl. The precipitate was filtered off, washed with water and dried to afford 6.1 g (81.9%) of 2-methyl-9- fluorenecarboxylic acid.
2-Methy1-9-fluorenemethanol
A solution of 2-methyl-9- fluorenecarboxylic acid (6 g, 26.8 mmol) in 300 mL of THF at 0°C was charged with 1M THF solution of BH3-THF complex (53.5 mL, 53.5 mmol). The reaction mixture was stirred overnight then quenched with 30 mL of 10% acetic acid in methanol and diluted with 300 mL of water. The layers were separated, the aqueous phase was extracted with ethyl acetate (3x50 mL), the combined extracts were dried over aagnesium sulfate and evaporated to give colorless oil.
Crystallization was accomplished upon treatment of the oil with 200 mL of hexane. Recrystallization from ethanol:water 4:1 afforded 4.55 g (80.6%) of 2- methyl-9-fluorenemethanol. N-(2-Methylfluorenyl-9-methoxycarbonyl)-L-leucine
A solution of 2-methyl-9-fluorenemethanol (2 g, 9.5 mmol) in 15 mL of methylene chloride was charged with 4.2 M phosgene solution in methylene chloride (1.8 g,18.4 mmol) at room temperature. The reaction was monitored by TLC (silica, 25% ethyl acetate in hexane). The reaction mixture was stirred at room temperature for 6 days. Excess of phosgene was removed by bubbling argon. The solvent was evaporated to produce a slightly yellow oil. The solution of the oil in 10 mL dioxane, at room temperature was charged with a solution of L- leucine (1.62 g, 12.3 mmol) in a mixture of 42 mL 10% aqueous potassium carbonate and 21 mL dioxane. The reaction mixture was stirred for 3 hr then diluted with water (20 mL). The aqueous layer was extracted with ethyl acetate (5x10 mL) then
acidified to pH 2 with HCl. The resulting oil was extracted with ethyl acetate (4x30 mL). The organic extracts were combined, washed with 1N HCl (2x30 mL) followed by washing with water, brine and
evaporation of the solvent. The crude product was purified by column chromatography using RP-18
Silica, and 7:3 mixture of methanol: water as the eluent. This afforded 1.3 g (74.7%) of the desired compound as colorless solid, mp 125-7°C.
EXAMPLE 18 N-[(2-Methoxyfluoren-9-ylmethoxy)carbonyl]-L-leucine (NPC 15489)
2-Methoxy-9-fluorenone
A solution of 2-hydroxyfluorenone (5 g, 25.5 mmol) in 500 mL methylene chloride was charged with 100 mL solution of 1N NaOH (4 g, 100 mmol), a solution of p-methyl tosylate (9.5 g, 51 mmol) in 200 mL of water and tetrabutylammonium hydrogen sulfate (0.2 g, catalytic) at room temperature. The reaction was monitored by TLC (silica, 25% ethyl acetate in hexane). The reaction mixture was stirred overnight at room temperature, the layers were separated. The organic layer was dried over MgSO4 and evaporated. Short path chromatography of the residual solid (silica, 5% ethyl acetate in hexane) afforded 3.8 g (71.0%) of the methylated product.
2-Methoxy-9-fluorenol
A solution of 2-methoxy-9-fluorenon (6 g, 28.5 mmol) in 30 mL of THF was charged with IM THF solution of BH3-THF complex (60 mL, 60 mmol) at 0°C. The reaction mixture was stirred for 6 hr at room temperature, then quenched with water (100 mL). The resulting precipitate was filtered off, washed with water and dried to afford 5.6 g (93.3%) of pure 2- methoxy-9-fluorenol.
2-Methoxyfluorene
2-Methoxy-9-fluorenol (5.5 g, 25.9 mmol) was charged with acetic anhydride (50 mL). The reaction mixture was heated to 50-60°C for 3 hr then diluted with methanol (100 mL) and hydrogenated over 20% palladium hydroxide on carbon(catalytic) for 10 hr at 60-70 psi of hydrogen. The catalyst was filtered off and the solvents were removed under reduced pressure. Recrystallization from methanol- water afforded 2.6 g of the product. An additional portion was obtained (0.2 g) by dilution of the filtrate with a small amount of water. The total amount of the product was 2.8 g (55.2%). 2-Methoxy-9-fluorenecarboxylic acid
A solution of 2-methoxyfluorene (2.7 g, 13.8 mmol) in 50 mL of THF at -78°C was charged with n-butyl lithium (0.93 g, 14.5 mmol). The reaction mixture was stirred for 15 min then CO2 gaseous (5 g, 113.6 mmol) was introduced via cannula over a period of 15 min at -78°C. The reaction mixture was warmed up to room temperature and stirred for additional 2 hr until a colorless solution was obtained. The reaction mixture was diluted with 100 mL of water and 100 mL of ethyl acetate. The layers were separated, the aqueous phase was washed with ethyl acetate (5x25 mL) and acidified to pH 1 with
concentrated hydrochloric acid. The precipitate was filtered off, washed with water and dried to afford 2.2 g (66.7%) of 2-methoxy-9-fluorenecarboxylic acid as colorless solid.
2-Methoxy-9-fluorenemethanol
A solution of 2-methoxy-9- fluorenecarboxylic acid (2.2 g, 9.2 mmol) in 100 mL of THF at 0°C was charged with 1M THF solution of BHj-THF complex (20 mL, 20 mmol). The reaction mixture was stirred overnight then quenched with 10 mL of 10% acetic acid in methanol and diluted with 100 mL of water. The layers were separated, the aqueous phase was extracted with ethyl acetate (3x25 mL). The combined extracts were dried over
magnesium sulfate and evaporated. The residue was crystallized from methanol-water to afford 1.87 g (87.0%) of product. N-{[9H-(4-Methylfluoren-9-yl)methoxy]carbonyl}-L- leucine
A solution of 2-methoxy-9-fluorenemethanol
(1.2 g, 5.3 mmol) in 20 mL of anhydrous methylene chloride and 10 mL of anhydrous THF was charged with 4.2 M of phosgene solution in methylene chloride
(2.38 mL, 10 mmol) at room temperature. The
reaction was monitored by TLC (silica, 25% ethyl acetate in hexane). The reaction mixture was stirred at room temperature for 3 hr. The excess of phosgene was removed by argon bubbling. The solvent was evaporated to afford a slightly yellow oil. A solution of the oil in 5 mL of dioxane was charged with a solution of L-leucine (0.53 g, 4 mmol) in 14 mL of 10% aqueous solution of potassium carbonate and 7 mL of dioxane at room temperature. The reaction mixture was stirred overnight and diluted with water (100 mL). The water layer was extracted with ethyl acetate (5x30 mL) then acidified to pH 2 with HCl. The resulting oil was extracted with ethyl acetate (3 x30 mL). The organic extracts were combined, washed with IN HCl (2x30 mL) followed by washing with water, brine and evaporation of the solvent. The crude product was purified by
recrystallization from ether-hexane mixture to afford 0.4 g (18.9%) of the desired product, mp 129- 131°C. EXAMPLE 19
N-[9H-(2,3-Benzofluoren-9-ylmethoxy)carbonyl]- L-leucine (NPC 15510) 2,3-Benzofluorene-9-carboxylic acid.
To a stirred, cooled (-78°C) suspension of 6.73 g (31.1 mmol) of 2,3-benzofluorene in 75 mL of THF was added 13.2 mL (31.0 mmol) of 2.35 M n-BuLi in hexanes dropwise. The resulting dark green mixture was stirred for 2 h and CO, gas generated from dry ice was passed into the reaction vessel for 1 h. The resulting pink mixture was warmed to room temperature, poured into water and washed twice with Et,0. The combined organic layers were concentrated at reduced pressure, poured into water and washed with Et2O. The combined aqueous layers were
acidified with concentrated HCl and the precipitated solid was collected by vacuum filtration. Drying in vacuo afforded 5.69 g (71%) of the desired
carboxylic acid, mp > 225°C (decomposition).
9-(2,3-Benzofluorenyl)methanol
To a stirred, cooled (0°C) suspension of
5.66 g (21.7 mmol) of 2,3-benzofluorene-9-carboxylic acid in 25 mL of THF was added 22 mL (22.0 mmol) of 1.0 M BH3 THF dropwise. The resulting yellow solution was allowed to warm to room temperature and stirred overnight. The mixture was quenched with 3 mL of 1:1 acetic acid-water and concentrated at reduced pressure. The resulting solid was dissolved in EtOAc and washed with saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine and dried over magnesium sulfate. Solvent was removed at reduced pressure to afford 4.45 g (83%) of a yellow solid which was used without any further purification, mp 148-152°C.
9-(2,3-Benzofluorenyl)methyl chloroformate
To a stirred suspension of 4.40 g (17.8 mmol) of 9-(2,3-benzofluorenyl)methanol in 12 mL of methylene chloride was added 4.5 mL (18.9 mmol) of 4.2 M phosgene in methylene chloride. The mixture was allowed to stir for 48 h and solvent was removed at reduced pressure. The resulting reddish-brown solid was dried in vacuo to afford 5.01 g (91%) of the crude chloroformate which was used without any further purification.
N-[9H-(2,3-Benzofluoren-9-ylmethoxy)carbonyl]-L- leucine, tert-butyl ester
To a stirred solution of 3.20 g (17.1 mmol) of L-leucine tert-butyl ester in 10 mL of methylene chloride was added 1.83 g (17.2 mmol) of
Na2CO3. The mixture was stirred for 10 min and 5.00 g (16.2 mmol) of crude 9-(2,3- benzofluorenyl) methyl chloroformate was added. A mild exothermic reaction occured and stirring was continued overnight. The mixture was poured into water and the aqueous layer was extracted with methylene chloride. The combined organic layers were washed with brine and dried over magnesium sulfate. Solvent v/as removed at reduced pressure and the crude product was chromatographed on 250 g of flash silica gel eluting with 15 % EtOAc in hexane to afford 4.76 g (64%) of tert-butyl ester as a yellow solid, mp 51-55°C.
N-[9H-(2,3-Benzofluoren-9-ylmethoxy)carbonyl]-L- leucine
To a stirred solution of 4.76 g (10.3 mmol) of N-[9H-(2,3-benzofluoren-9- ylmethoxy)carbonyl]-L-leucine, tert-butyl ester in
10 mL of methylene chloride was added 10 mL of trifluoroacetic acid. The mixture was stirred overnight and solvent was removed at reduced
pressure. The crude product was chromatographed on 175 g of flash silica gel eluting with 25% EtOAc in hexane followed by 40% EtOAc in hexane to afford a dark yellow solid. Recrystallization from EtOAc- hexane afforded 2.35 g (56%) of analytically pure sample as a pale yellow solid, mp 168-177°C.
EXAMPLE 20
N-[(9H-Fluoren-9-ylethoxy)carbonyl]- L-leucine (NPC 15521)
2-(9-Fluorenyl)ethanol
To a stirred, cooled (-78°C) solution of
6.00 g (36.1 mmol) of fluorene in 75 mL of THF was added 15.4 mL (36.2 mmol) of 2.35 M n-BuLi in hexanes dropwise. The resulting dark orange mixture was stirred for 1.5 h and 26.0 mL (36.4 mmol) of 1.4
M ethylene oxide in Et2O was added. The resulting bright orange mixture was warmed slowly to room temperature over 3.5 h, quenched with saturated aqueous NH4Cl and concentrated at reduced pressure.
The residue was poured into water and extracted twice with Et2O. The combined organic layers were washed with brine and dried over magnesium sulfate.
Solvent was removed at reduced pressure and the crude product was chromatographed on 150 g of flash silica gel eluting with 25% EtOAc in hexane to afford 5.05 g (67%) of the desired alcohol as a white solid, mp 98-99°C. 2-(9-Fluorenyl)ethyl chloroformate
To a stirred, cooled (0° C) suspension of 4.50 g (21.4 mmol) of 2-(9-fluorenyl)ethanol in 10 mL of methylene chloride was added 10.0 mL (42.0 mmol) of 4.2 M phosgene in methylene chloride. The resulting homogeneous yellow mixture was warmed to room temperature and stirred for 72 h. Solvent was removed at reduced pressure and the resulting dark green viscous oil was dried in vacuo to afford 5.74 g (98 %) of the crude chloroformate which was used without any further purification.
N-[(9H-Fluoren-9-ylethoxy)carbonyl]-L-leucine tert- butyl ester
To a stirred solution of 3.48 g (18.6 mmol) of L-leucine tert-butyl ester in 15 mL of methylene chloride was added 2.00 g (18.9 mmol) of
Na2CO3. The suspension was stirred for 15 min and
5.00 g (18.3 mmol) of crude 2-(9-fluorenyl)ethyl chloroformate was added. A mild exothermic reaction occured and stirring was continued overnight. The mixture was poured into water and the aqueous layer was extracted with methylene chloride. The combined organic layers were washed with brine and dried over magnesium sulfate. Solvent was removed at reduced pressure and the crude product was chromatographed on 400 g of flash silica gel eluting with 10% EtOAc in hexane to afford 6.65 g (86%) of tert-butyl ester as a viscous pale yellow oil.
N-[(9H-Fluoren-9-ylethoxy)carbonyl]-L-leucine
To a stirred solution of 6.63 g (15.6 mmol) of N-[(9H-fluoren-9-ylethoxy)carbonyl]-L- leucine tert-butyl ester in 10 mL of methylene chloride was added 10 mL of trifluoroacetic acid.
The mixture was stirred for 2.5 h and solvent was removed at reduced pressure. The crude product was chromatographed on 150 g of flash silica gel eluting with 25% EtOAc in hexane followed by 50% EtOAc in hexane to afford 5.32 g (92%) of product as a white solid, mp 42-43°C.
EXAMPLE 21
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-leucine t-butyl ester (NPC 15527)
A solution of 9-fluorenemethoxycarbonyl- O-succinimide (9 g, 26.7 mmol) in methylene chloride (50 ml) was charged with leucine-t-butyl ester (5 g, 26.7 mmol). After 24 hours at room temperature the reaction mixture was thoroughly washed with water (x6), dried over magnesium sulfate and evaporated. Recrystalyzation from hexane (very small amount of
EtOAc was added to increase solubility) afforded 6.5 g (59.5%) of the product as colorless solid, mp 183- 4°C. EXAMPLE 22
N-[(9H-Fluoren-9-ylmethoxy)carbonyl] L-leucine amide (NPC 15528)
A solution of N-[(9H-fluoren-9- ylmethoxy)carbonyl]-L-leucine, acid chloride (3.5g, 10 mmol) in 10 mL of THF was charged with NH3 (29.6% water solution, 1.26 mL, 20 mmol) at room
temperature. The reaction mixture was stirred for 30 min., then diluted with 100 mL of water and extracted with ethyl acetate (5x20 mL). The organic layers were combined, extracted with 10% potassium carbonate solution, washed with water, brine, dried and evaporated. Recrystallization of the product from ethanol afforded 1.26 g (36%) of N-(9- fluorenylmethoxycarbonyl)-L-leucine, amide as colorless solid, mp 79-80°C. EXAMPLE 23
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine methylamide (NPC 15529) A solution of N-[(9H-fluoren-9- ylmethoxy)carbonyl]-L-leucine, acid chloride (3.5 g, 10 mmol) in 50 mL of THF was charged with solution of methylamine (0.62 g, 20 mmol) in 50 mL of
dichloromethane, at room temperature. The reaction mixture was stirred for 30 min. The solvents were removed and the residue was dissolved in 100 mL of ethyl acetate. The solution was washed with aqueous solution of 10% potassium carbonate, water, brine, dried over magnesium sulfate and evaporated.
Recrystallization of the product from ethyl
acetate/hexane mixture afforded 1.67g (46.6%) of N- [(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucine
methylamide, mp 173-174°C. EXAMPLE 24
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]- L-tert-leucine, (NPC 15573)
A solution of L-tert-Leu (2 g, 15.3 mmol) in 100 mL of dichloromethane, at room temperature, was charged, with F-MOC-O-succinimide (5.4 g, 16 mmol) and catalytic amount of DMAP. The reaction mixture was stirred for 48 hr. A solution of 10% aqueous potassium carbonate (50 mL) was added, and the mixture was stirred for additional 5 hr. The layers were separated, the water layer was diluted with 10% potassium carbonate solution (50 mL), extracted with ethyl acetate (3x30 mL) then
acidified to pH 1. The oil was separated from the water layer, mixed with IN HCl (30 mL) and extracted with ethyl acetate. The organic solution was washed with 1N HCl, water, brine and evaporated.
Recrystallization of the product from ethyl
acetate/hexane mixture afforded 2.3 g (40.6%) of F- MOC-L-tert-leucine as white solid, mp 122-124°C. EXAMPLE 25
N-{[9H-(1-Methylfluoren-9-yl)methoxy]carbonyl}- L-leucine (NPC 15638) 1-Methyl-9-fluorenecarboxylic acid
A solution of 1-methylfluorene (3.8 g, 21.1 mmol) in 100 mL of THF at -78°C was charged with n-butyl lithium (3.5M solution in hexane, 6.29 ml, 22.0 mmol). The reaction mixture was stirred for 15 min, then CO2 gaseous (5 g, 113.6 mmol) was introduced via cannula over a period of 15 min. The reaction mixture was warmed up to room temperature and stirring was continued until no color was apparent (approximately 2 hr). The slurry was diluted with water (100 mL) and ethyl acetate (50 mL). The layers were separated, the water layer was washed with ethyl acetate (3x50 mL), then acidified with cone. HCl. The precipitate was collected, washed with water and dried to give 1-methyl-9- fluorenecarboxylic acid (4.02 g, 84.8%).
1-Methyl-9-fluorenemethanol
A solution of 1-methyl-9- fluorenecarboxylic acid (4.0 g, 17.9 mmol) in 100 mL of THF was charged with 1M THF solution of BH3-THF complex (35 mL, 35 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature then quenched with water (20 mL). The organic layer was washed with 10% potassium carbonate solution, water, brine, dried and evaporated to afford 1- methyl-9-fluorenemethanol (3.2 g, 84.9%). N-{[9H-(1-MethyIfluoren-9-yl)methoxy]carbonyl}-L- leucine
A solution of 1-methyl-9-fluorenemethanol
(3.0 g, 14.3 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 40 mL) was charged with a solution 4.2 M of phosgene in methylene chloride (5 mL, 21.0 mmol), at room temperature. The reaction mixture was stirred for 3 hr, then the excess of the phosgene was removed by bubbling argon. The solvents were removed, the residual oil was
dissolved in 10 mL of dioxane and the solution was added to a solution of L-leucine (1.97 g, 15 mmol) in 22 mL of dioxane and 45 mL of 10% aqueous
potassium carbonate at room temperature. The reaction mixture was stirred for two days, diluted with 150 mL of water and extracted with ethyl acetate (5x25 mL). The water layer was acidified to pH 1. The precipitated oil was extracted with ethyl acetate (3x50 mL), the organic solutions were washed with 1N HCl (3x20 mL), water, brine, dried over magnesium sulfate and evaporated to give an oil which was solidified by stirring in an ether-hexane mixture. The compound was purified by a column chromatography on silica using a solution of
methanol: chloroform 95:5 as eluent. A second chromatography with RP-18 silica using
methanol: water 7:3 afforded 1.3 g (24.7%) of the desired compound, mp 125-128°C.
EXAMPLE 26
N-{[9H-(2,7-Dimethylfluoren-9-yl)methoxy]- carbonyl}-L-lcucine (NPC 15669)
4,4'-Dimethyldiphenic acid
Diazotation of the methyl anthranilic acid: a mixture of 2-amino-5-methylbenzoic acid (50.0 g, 330.8 mmol), water (136 mL) and cone. HCl (97.4 mL) was charged with a solution of sodium nitrite (23.8 g, 340.0 mmol) in 136 mL of water at 0-5°C during 30 min. The resulting diazonium solution was filtered and kept at a temperature below 5°C before further use.
A solution of hydrated cupric sulfate
(114.0 g, 457.6 mmol) in 454 mL of water was treated with concentrated ammonium hydroxide solution
(sp.gr. 0.90, 190.4 mL). A solution of
hydroxylammonium chloride (32.2 g, 464.0 mmol) in of water (108 mL) was charged with 6N sodium hydroxide (77 mL) at 5-10°C.
The resulting hydroxylamine solution was immediately added to the cupric sulfate solution.
The resulting solution at 5-10°C was charged with the diazonium solution at the same temperature during 40-50 min (the rate of addition is about 10 cc per minute) with a vigorous stirring. Stirring was continued for 5 min then heated to 70°C and acidified with conc. HCl. The mixture was allowed to stand overnight. The precipitate was filtered off, washed with water and dissolved in 400 mL of 10% sodium bicarbonate solution. This solution was treated with Norit, then filtered and acidified with 6N HCl. The precipitated product weighed 40.4 g (90.4 %).
2,7-Dimethylfluorenone
4,4-Dimethyldiphenic acid (20.0 g, 74.0 mmol) was heated in a sand bath at 300-330°C for 2 hr until decarboxylation was over (no gas was evolved). The reaction mixture was cooled down to room temperature and the cake obtained was dissolved in acetone. Evaporation of the acetone produced a black material which was extracted with 25% solution of ethyl acetate in hexane. Evaporation of the solvents afforded the crude ketone which was further purified on a short path chromatography (silica, a. hexane, b. 5% ethyl acetate in hexane). This afforded 10.1 g (65.4%) of 2,7-dimethylfluorenone.
2,7-Dimethylfluorene
A mixture of 2,7-dimethylfluorenone (7.0 g, 32.8 mmol), methanol (100 mL), ethyl acetate (50 mL), acetic acid (20 mL) and palladium hydroxide (20% on carbon, water content 44.43%, 0.5g) was hydrogenated in a shaker at 26 psi of hydrogen for 4 hr. The reaction was monitored by TLC (silica, 10% ethyl acetate/hexane). The catalyst was filtered out and the solvents were removed in vacuum.
Treatment of the residue with methanol afforded 5.7 g (89.3%) of 2,7-dimethylfluorene. 2,7-Dimethyl-9-fluorenecarboxylic acid
A solution of 2,7-dimethylfluorene (5.0 g, 25.7 mmol) in THF (100 mL) at -78°C was charged with butyl lithium (16.8 mL, 26.0 mmol). The reaction mixture was stirred for 15 min, then CO2 gaseous (5g, 113.6 mmol) v/as introduced with cannula over a period of 15 min at -78°C. The reaction mixture was warmed up to room temperature and stirred overnight, diluted with water (150 mL). The layers were separated, the water layer was washed with ethyl acetate (5x20 mL), then acidified with cone. HCl. The precipitate formed was collected, washed with water and dried to give 4.4 g of 2,7-dimethyl-9- fluorenecarboxylic acid (72.4%).
2,7-Dimethyl-9-fluorenemethanol
A solution of 2,7-dimethyl-9- fluorenecarboxylic acid (4.3 g, 18.0 mmol) in THF
(100 mL) was charged with IM THF solution of BH3-THF complex (36.0 mL, 36.0 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature then quenched with water (100 mL) and HCl (3 mL). After addition of ethyl acetate (50 mL) the organic layer was separated and washed with 10% potassium carbonate solution, water, brine, dried over
magnesium sulfate and evaporated to afford 2,7- dimethyl-9-fluorenemethanol (3.0 g, 74.4%).
N-{[9H-(2,7-DimethyIfluoren-9-yl)methoxy]carbonyl}- L-leucine
A solution of 2,7-dimethyl-9- fluorenemethanol (3.0 g, 13.4 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 50 mL) was charged with 4.2 M methylene chloride solution of phosgene (4.8 mL, 20.1 mmol) at room temperature. The reaction mixture was stirred overnight at room temperature, then an additional portion of phosgene (2.4 mL, 10.1 mmol) was added and the reaction mixture was stirred for additional 4 hr. The excess of the phosgene was removed by bubbling of argon. The solvents were removed under reduced pressure, the residue (a slightly pink crystals) was dissolved in 10 mL of dioxane and the solution was added to a solution of L-leucine (1.71 g, 13.0 mmol) in 25.0 mL of dioxane and 10% potassium carbonate solution (49.0 mL) at room temperature. The reaction mixture was stirred overnight, the dioxane was removed under reduced pressure, the residue was diluted with 150 mL of water. The water layer was extracted with ethyl acetate (5x25 mL), the combined organic extracts were washed 10% potassium carbonate solution, then twice with water. These water layers were combined with the original aqueous basic solution and the resulting solution was acidified to pH 1 with cone. HCl. The solid formed was filtered off and dried. The compound was purified by a column chromatography: silica RP-18, methanol:water 7:3. This afforded 2.74 g (57.3 %) of the desired compound, mp 163-166°C. EXAMPLE 27
N-{[9H-(2,7-DimethyIfluoren-9-yl)methoxy]carbonyl}- L-leucine (NPC 15670) 6,6-Dimethyldiphenic acid
Diazotation of the methyl anthranilic acid: a mixture of 2-amino-3-methylbenzoic acid (50.0 g, 330.8 mmol), water (136 mL) and cone. HCl (97.4 mL) was charged with a solution of sodium nitrite (23.8 g, 340.0 mmol) in 136 mL of water at 0-5°C during 30 min. The resulting diazonium solution was filtered and kept at a temperature below 5°C before further use.
A solution of hydrated cupric sulfate (114.0 g, 457.6 mmol) in 454 mL of water was treated with concentrated ammonium hydroxide solution
(sp.gr. 0.90, 190.4 mL). A solution of
hydroxylammonium chloride (32.2 g, 464.0 mmol) in of water (108 mL) was charged with 6N sodium
hydroxide (77 mL) at 5-10°C. The resulting
hydroxylamine solution was immediately added to the cupric sulfate solution.
The resulting solution was cooled to 5-
10°C then was charged with the diazonium solution at the same temperature during 40-50 min (the rate of addition is about 10 cc per minute) with a vigorous stirring. Stirring was continued for 5 min then heated to 70°C and acidified with cone. HCl. The mixture was allowed to stand overnight. The
precipitate was filtered off, washed with water and dissolved in 400 mL of 10% sodium bicarbonate
solution. This solution was treated with Norit, then filtered and acidified with 6N HCl. The
precipitated product weighed 38.4 g (85.9%).
4,5-Dimethylfluorenone
4,4-Dimethyldiphenic acid (20.0 g, 74.0 mmol) was charged with polyphosphoric acid (83.4 g) at room temperature. The mixture was heated in an oil bath at 120-121°C for 6.5 hr until
decarboxylation was over (no gas evolved). The
reaction mixture was cooled down to 60°C, diluted with water (150 mL) then cooled down to room
temperature. The precipitate was filtered off, washed with water, 10% sodium bicarbonate solution until the filtrate became colorless, extracted with 25% solution of ethyl acetate in hexane and dried over magnesium sulfate. Evaporation of the solvents gave the crude ketone which was purified by short path chromatography (5% ethyl acetate in hexane).
This afforded 10.8 g (70.4%) of 4,5-dimethylfluorenone. 4,5-Dimethylfluorene
A mixture of 4,5-dimethylfluorenone (7.0 g, 32.8 mmol), methanol (100 mL), ethyl acetate (50 mL), acetic acid (20 mL) and palladium hydroxide (20% on carbon, water content 44.43%, 1.0 g) was hydrogenated in a shaker at 35-40psi of hydrogen for 3.5 hr. The reaction was monitored by TLC (silica, 10% ethyl acetate/hexane). The catalyst was
filtered off and the solvent was removed in vacuum, the residue was diluted with water (150 mL). The product was extracted with ethyl acetate (3x50 mL) and dried over magnesium sulfate. Evaporation of the solvent afforded 5.8 g (91.2%) of
4,5-dimethylfluorene.
4,5-Dimethyl-9-fluorenecarboxylic acid
A solution of 4,5-dimethylfluorene (5.2 g, 27.0 mmol) in 100 mL of THF at -78° C was charged with butyl lithium ( 18 . 7 mL, 29.0 mmol). The reaction mixture was stirred for 15 min, then CO2 gaseous (5 g, 113.6 mmol) was introduced via cannula over a period of 15 min at -78°C. The reaction mixture was warmed up to room temperature and stirred overnight. Water was added (150 mL) and the layers were separated, the water layer was washed with ethyl acetate (5x20 mL), then acidified with cone. HCl. The precipitate was collected, washed with water and dried to give 2,7-dimethyl-9- fluorenecarboxylic acid (4.24 g, 65.9 %).
4,5-Dimethyl-9-fluorenemethanol
A solution of 4,5-dimethyl-9- fluorenecarboxylic acid (4.2 g, 17.8 mmol) in 100 mL of THF was charged with 1M THF solution of BH3-THF complex (25.0 mL, 25.0 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature then quenched with water (100 mL) and HCl (3 mL). After addition of ethyl acetate (50 mL) the organic layer was separated and washed with 10% potassium carbonate solution, water, brine, dried dried over magnesium sulfate and evaporated to afford 4 . 5- dimethyl-9-f luorenemethanol ( 3 . 0 g , 75 . 3 % ) .
N- { [ 9H- (2 , 7 -Dimethylf luoren-9 -yl ) methoxy] carbonyl } - L-leucine
A solution of 2 , 7 -dimethyl-9- fluorenemethanol (3.0 g, 13.4 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 50 mL) was charged with a 4.2 M solution of phosgene (4.8 mL, 20.1 mmol) in methylene chloride at room
temperature. The reaction mixture was stirred for 4 hr at room temperature. The excess of the phosgene was removed by bubbling argon. The solvents were removed under reduced pressure, the residue was dissolved in 10 mL of dioxane and the solution was added to a solution of L-leucine (1.71 g, 13.0 mmol) in 25.0 mL of dioxane and 49.0 mL of 10% potassium carbonate solution at room temperature. The reaction mixture was stirred overnight, the dioxane was removed under reduced pressure and the residue was diluted with 150 mL of water. The water layer was extracted with ethyl acetate (5x25 mL), the combined organic extracts were washed 10% aqueous solution of potassium carbonate, then twice with water. These water layers were combined with the original aqueous basic solution and the resulting solution was acidified to pH 1 with cone. HCl. The precipitate was filtered off and dried. The compound was purified by a column chromatography: silica RP-18, methanol:water 7:3. This afforded
1.94 g (38.1 %) of the desired compound as white solid, mp 135-139°C. EXAMPLE 28
N-{9H-[3-(2-Methylfluoren-9-yl)propionyl]}- L-leucine (NPC 15671)
3-(2-MethyIfluoren-9-yl)-1,3-dioxolane
A solution of BuLi (2.35M in hexane, 20.5 mL, 47.9 mmol) was slowly added into a cooled
(-78°C) solution of 2-methylfluorene (8.2 g, 45.5 mmol) in 200 mL THF. The reaction mixture turned dark red and solid started to precipitate out.
After 30 minutes 2-(2-bromoethyl)-1,3-dioxolane
(9.1 g, 50.3 mmol) was added to the cold solution and the solution was warmed up to room temperature. TLC (silica, 5% EtOAc in hexane) was used to monitor the reaction. After two hours, the reaction was quenched with water, the solution was concentrated and the product was extracted into EtOAc. The organic layer was washed with water (x3), dried over magnesium sulfate and evaporated. Short path chromatography (silica, 5% EtOAc in hexane) afforded
9.4 g.
3-(2-Methylfluoren-9-yl)propionic acid
A solution of 3-(2-methylfluoren-9-yl)-
1,3-dioxolane (9.0 g, 32 mmol) in 350ml acetone at 0°C was slowly charged with 350 mL of Jone's reagent (the reagent was made by dissolving 16 g of chromium trioxide and 64 mL of concentrated sulfuric acid in 400 mL of water). A very strong reaction was observed during the addition of the oxidant. The temperature raised to room temperature after all the reagent was added. The reaction mixture was monitored by TLC (silica, 25% EtOAc in hexane). The reaction was completed within 5 hr. The product was extracted with EtOAc and the organic layer was washed thoroughly with water (x6), until aqueous washings were clear and colorless.
Recrystallization from MeOH:water afforded 6.3 g.
N-{9H-[3-(2-Methylfluoren-9-yl)propionyl]}-L-leucine
A solution of 3-(2-methylfluoren-9- yl)propionic acid (4.13 g, 16.4 mmol) and leucine t- butyl ester (3.4 g, 18 mmol) in methylene chloride at room temperature (60 mL) was charged with 1-(3- dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (3.45 g, 18 mmol). Catalytic amount of DMAP (ca 50 mg) was added. After two hours at room temperature, TLC (silica, 25% EtOAc in hexane) indicated the completion of the reaction. The methylene chloride was removed in vacuum and EtOAc was introduced. The organic solvent was washed with water (κ2), 10% aqueous potassium carbonate and water again, dried over magnesium sulfate and evaporated. The resulting oil was filtered through a short column of silica with 25% EtOAc in hexane. The crude oil was stirred overnight, at room temperature in in 1:1 trifluoroacetic acid:
methylene chloride (60 mL). The solvents were removed in vacuum and the resulting oil was
recrystallized from EtOAc: hexane to afforded 3.0 g (50.0%), mp 196-200°C.
EXAMPLE 29
N-{[9H-(1-Methoxymethylfluoren-9- yl)methoxy]carbonyl}-L-leucine (NPC 15673)
1-Fluorenemethanol
A solution of 1-fluorenecarboxylic acid (10.0 g, 47.6 mmol) in THF (150 mL) at 0°C was charged with a IM solution of BH3-THF complex in THF (80 mL, 80 mmol). The reaction mixture was stored overnight at room temperature then quenched with 30 mL of 10% AcOH in methanol. After dilution with water (100 mL), the water layer was extracted with ethyl acetate (3x50 mL). The combined organic extracts were washed with 10% potassium carbonate solution, water, brine, dried over magnesium sulfate and evaporated. The residue (white crystals) was washed with ether and dried to afford 1- fluorenemethanol (6.4 g, 68.5 %).
1-Methoxymethylfluorene
A solution of 1-fluorenemethanol (5.0 g,
25.6 mmol) in 50 mL of THF was charged with butyl lithium solution (11.0 mL, 26.0 mmol) at -78°C.
After 15 min of stirring iodomethane (25.1 g, 176.1 mmol) was introduced. The reaction mixture was stirrer for 3 days at room temperature. The reaction was monitored by TLC (silica, 25% ethyl acetate in hexane). As soon as no more starting material was detected the reaction was quenched with water (30 mL). The organic layer was separated, washed with water, brine, dried over magnesium sulfate and evaporated. A short path chromatography of the residual oil (silica, 5% ethyl acetate in hexane) afforded 4.5 g (70.0%) of 1- methoxymethylfluorene.
1-Methoxymethyl-9-fluorenecarboxylic acid
A solution of 1-methoxymethylfluorene (4.5 g, 21.4 mmol) in 100 mL of THF at -78°C was charged with butyl lithium (10.0 mL, 23.5 mmol). The reaction mixture was stirred for 15 min, then CO2 gaseous (5g, 113.6 mmol) was introduced via cannula over a period 15 min at -78°C. The reaction mixture was warmed up to room temperature and stirred for additional 2 hr until colorless, diluted with water (100 mL) and ethyl acetate (50 mL). The layers were separated, the water layer was washed with ethyl acetate (3x50 mL), then acidified with cone. HCl. The resulting precipitate was collected, washed with water and dried to give 1-methoxymethyl-9- fluorenecarboxylic acid (1.8 g, 33.1 %). 1-Methoxymethy1-9-fluorenemethanol
A solution of 1-methoxymethyl-9- fluorenecarboxylic acid (3.4 g, 13.4 mmol) in 100 mL of THF was charged with IM THF solution of BH3-THF complex (30.0 mL, 30.0 mmol) at 0°C. The reaction mixture was stirred overnight at room temperature then quenched with water ( 100 mL) . The organic layer was washed with 10% potassium carbonate solution, water, brine, dried over magnesium sulfate and evaporated. Short path chromatography of the residual oil (silica, 25% ethyl acetate in hexane) afforded 1-methoxymethyl-9-fluorenemethanol (2.6 g, 79.9 %).
N-{[9H-(1-Methoxymethyllfluoren-9- yl)methoxy]carbonyl}-L-leucine, quarter hydrate
A solution of 1-methoxymethyl-9- fluorenemethanol (2.6 g, 10.7 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 50 mL) was charged with 4.2 M solution of phosgene (3.8 mL, 16.1 mmol) in methylene chloride, at room
temperature. The reaction mixture was stirred for 4 hr at room temperature. The excess of the phosgene was removed by bubbling argon. The solvents were removed, the residual oil was dissolved in 10 mL dioxane and the solution was added to a solution of
L-leucine (1.31 g, 10.0 mmol) in 18.0 mL of dioxane and 37.5 mL of 10% potassium carbonate solution at room temperature. The reaction mixture was stirred overnight, diluted with 200 mL of water and
extracted with ethyl acetate (5x20 mL). The water layer was acidified to pH 1. The resulting oil was extracted with ethyl acetate (3x50 mL), the organic solutions were washed with IN HCl (3x20 mL), water, brine, dried over magnesium sulfate and evaporated to give an oil which was purified by a column chromatography (silica RP-18, 60% methanol in water) to afford 1.6 g (37.4 %) of the desired product, mp 63-66°C.
EXAMPLE 30
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L- neopentylglycine quarter hydrate (NPC 15676)
A solution of L-neopentylglycine (3.1 g, 21.5 mmol) in 10% aqueous potassium carbonate (40 ml) was added into a stirred solution of N-(9- fluorenylmethoxycarbonyl) succinimide (8.0 g, 23.7 mmol) in dioxane (100 ml). Catalytic amount of DMAP was added and the reaction mixture was stirred at room temperature for three hours. Most of the xylene was evaporated in vacuum. The resulting aqueous solution was washed with ether (x4). The aqueous solution was acidified with HCl and the precipitate was extracted with EtOAc. The organic phase was dried over magnesium sulfate and
evaporated. Short path chromatography (silica, 2.5% EtOAc in hexane) afforded 3.5 g (43.7%), mp 70- 73°C.
EXAMPLE 31 N-[3-(9H-Fluoren-9-yl)propionyl]-L-tert-leucine, quarter hydrate (NPC 15685)
N-[3-(9H-Fluoren-9-yl)propionyl]-L-t-leucine quarter hydrate
A solution of 3-(fluoren-9-yl)propionic acid (2.4 g, 10 mmol) in thionyl chloride was refluxed for two hours. The reaction mixture was cooled down and the solvent was removed in vacuum. A solution of the resulting 3-(fluoren-9- yl)propionic acid chloride was dissolved in dioxane (20 mL) and added into a solution of L-tert-leucine (4 g, 30.5 mmol) in 10% aqueous sodium carbonate (40 mL). The reaction mixture was monitored by
quenching an aliquot with methanol than monitor the resulting methyl ester by TLC (10% MeOH in
chloroform). After an 1.5 hr water was added and most of the dioxane was removed in vacuum. The aqueous layer was washed with diethyl ether (x3) then was acidified to pH 1 with 10% HCl. The resulting precipitate was purified by a short path chromatography (silica, 5% MeOH in chloroform) to yield 1.5 g (42.1%), mp 79-83°C.
EXAMPLE 32
N-{9H-[3-(1-Methylfluoren-9-yl)propionyl]}-L- tert-leucine, quarter hydrate (NPC 15885)
2-[2-(1-Methylfluoren-9-yl)ethyl]-1.3-dioxolane
1-Methylfluorene (3.2 g, 18.0 mmol) in 50 mL THF was charged with BuLi, 2.35M solution in hexanes (7.65 mL, 18.0 mmol) at -78°C. The reaction mixture was stirred for 2 hr at -78°C then 2-bromo-
1.3-dioxolane (3.6 g, 19.8 mmol) was added by a syringe. The reaction was monitored by TLC (silica, 10% ethyl acetate/hexane). The reaction mixture was stirred for 2 hr at room temperature then the THF was evaporated . The residue was dissolved in ethyl acetate. The solution was washed with water, dried over magnesium sulfate, treated with a coarse silica gel and Norit and evaporated to yield 4.8 g (96.6%) of the desired product.
3-(1-Methylfluoren-9-yl)propionic acid
2-[2-(1-Methylfluoren-9-yl)ethyl]-1,3- dioxolane (4.8 g, 17.2 mmol) in 100 mL of acetone was charged slowly with John's reagent (CrO3:
H2SO4:H2O 4:4:50 by weight) at room temperature. The reaction was monitored by TLC (silica, 10% ethyl acetate/hexane). The reaction mixture was stirred for 6 hr at room temperature, the acetone was evaporated and the residual water was extracted with ethyl acetate twice. The combined organic layers were washed with water until water became colorless. The organic solution was then extracted with 1N aqueous solution of sodium hydroxide. The basic aqueous solution was washed with ethyl acetate, acidified and extracted with ethyl acetate again. The ethyl acetate solution was dried over magnesium sulfate and evaporated. Purification of the crude by short path chromatography (silica, 25% ethyl acetate/hexane) afforded 2.6 g (59.9%) of 3-(1- methylfluoren-9-yl)propionic acid.
3-(1-Methylfluoren-9-yl)propionyl chloride
3-(1-Methylfluoren-9-yl)propionic acid
(2.5 g, 9.9 mmol) was charged with SOCl2 (20 mL, in excess) at room temperature. The reaction mixture was boiled for 2 hr. Excess of thionyl chloride was removed under reduced pressure. The residual oil was used for the next step without further
purification.
N-{9H-[3-(1-Methylfluoren-9-yl)propionyl]}-L-tert- leucine, quarter hydrate
The compound 3-(1-methylfluoren-9- yl)propionyl chloride (2.7 g, 9.9 mmol) in 80 mL dioxane was charged with a solution of L-tert- leucine (1.6 g, 11.9 mmol) in 25 mL of 10% aqueous solution of potassium carbonate at room temperature. The reaction mixture was stirred overnight. The dioxane was removed under reduced pressure. The residue was diluted with water (100 mL), washed with ether (twice) then acidified to pH 1. The compound was extracted with ethyl acetate. Short path
chromatography (Silica, 25% then 50% ethyl
acetate/hexane) afforded 1.89 g (51.5%) of N-{9H- [3-(1-methylfluoren-9-yl)propionyl]}-L-tert-leucine, quarter hydrate, mp 89-94°C.
EXAMPLE 33
N-[3-(9H-Fluoren-9-yl)propionyl]-L-norleucine, quarter hydrate (NPC 15894)
3-(Fluoren-9-yl)propionyl chloride
3-(Fluoren-9-yl)propionic acid (15.0 g, 62.9 mmol) was charged with S0C1, (20 mL, in excess) at room temperature. The reaction mixture was boiled for 2 hr. The reaction was monitored by TLC (silica RP-18, 70% methanol in water). Excess of thionyl chloride was removed under reduced pressure, the residue was crystallized from ethyl
acetate/hexane mixture to give 10.1 g (62.5%) of the desired product. The product was not stable enough to be characterized and was used immediately for the next step. N-[3-(9H-Fluoren-9-yl)propionyl]-L-norleucine, quarter hydrate
Crude 3-(fluoren-9-yl)propionyl chloride
(without crystallization) (4.5 g, 17.5 mmol) in 20 mL of dioxane was added very slowly to a cooled (0°C) solution of L-norleucine (2.7 g, 20.0 mmol) in
100 mL of 10% aqueous solution of sodium carbonate and 50 mL of dioxane. The reaction mixture was stirred for 1 hr at room temperature, diluted with water (50 mL) and extracted v/ith ethyl acetate (2x25 mL). The water solution was cooled to 0°C then acidified to pH 1 with 10% HCl. The semicrystalline residue was recrystallized from methanol/water. A pure sample was obtained after careful washing of the solid with ether. This afforded 1.7 g (27.4%) of N-[9H-(3-fluoren-9-ylpropionyl)]-L-norleucine, quarter hydrate, mp 167-169°C. EXAMPLE 34
N-[3-(9H-Fluoren-9-yl)propionyl]-L- Homophenylalanine, quarter hydrate (NPC 15895) Crude 3-(fluoren-9-yl)propionyl chloride
(described in Example 33, without crystallization) (3.8 g, 14.7 mmol) in dioxane (15 mL) was added very slowly to a cooled (0°C) solution of L- homophenylalanine (2.7 g, 15.0 mmol) in 10% aqueous solution of sodium carbonate (90 mL) and 45 mL of dioxane. The reaction mixture was stirred for 1 hr at room temperature, diluted with water (100 mL) and extracted with ethyl acetate (3x25 mL). The water solution was cooled to 0°C then acidified to pH 1 with 10% HCl. The precipitate was filtered off, washed with water, dried and carefully washed with ether (3x50 mL) to afford 1.7 g (28.6%) of N-[9H- (3-fluoren-9-ylpropionyl)]-L-homophenylalanine, quarter hydrate, mp 166-168°C.
EXAMPLE 35
N-[3-(9H-Fluoren-9-yl)propionyl]-L- Phenylalanine (NPC 15896)
3-(Fluoren-9-yl)propionyl chloride
(described in Example 33; without crystallization) (3.0 g, 11.7 mmol) in dioxane (40 mL) was added to a stirred solution of L-phenylalanine ((2.0 g, 11.7 mmol) in 75 mL of 10% potassium carbonate solution and 38 mL of dioxane at room temperature. The reaction mixture was stirred overnight. The dioxane was removed under reduced pressure. The residue was diluted with water (100 mL) and extracted with ethyl acetate (4x30 mL). The water solution was treated with Norit then acidified to pll 1. The precipitate was filtered off, washed with IN HCl, water and dried. Short path chromatography (RP-18 Silica, 50% methanol/water) afforded white solid. Final
purification was accomplished by washing the product with ether. The resulting yield of N-[9H-(3- fluoren-9-ylpropionyl)]-L-phenylalanine was 1.2 g (26.5%), mp 194-195°C.
EXAMPLE 36
N-{[9H-(4-Methylfluoren-9-yl)methoxy]carbonyl}- L-tert-leucine (NPC 15904)
A solution of 4-methyl-9-fluorenemethanol (from Example 10, 4.5g, 21.5 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 50 mL) was charged with a solution of 4.2 M phosgene of 4.2 M phosgene methylene chloride (6 mL, 25.0 mmol) at room temperature. The reaction mixture was stirred for 24 hr at room temperature, then the excess of the phosgene was removed by bubbling argon. The solvents were removed in vacuum. The residual oil was treated with hexane (200 mL). The solids were removed by filtration and the solution was
evaporated. The resulting oil was dissolved in dioxane (25 mL) then added to a solution of L-tert- leucine (2.9 g, 22.5 mmol) in a mixture of dioxane (34 mL) and 10% aqueous solution of potassium carbonate (68 mL) at room temperature. The reaction mixture was stirred overnight, diluted with water and extracted with ethyl acetate (5x30 mL). The water layer was acidified to pH 1. The precipitate was filtered, washed with water and dried. Short path chromatography (RP-18 Silica, 70%
methanol/water) afforded an oil. The oil was dissolved in a solution of 10% aqueous potassium carbonate followed by precipitation with diluted HCl. Recrystallization from methanol/water (1:1) afforded 1.45 g (18.1%) of the desired compound, mp 91-125°C.
EXAMPLE 37
N-{[9H-(1-Methylfluoren-9-yl)methoxy]carbonyl}- L-norleucine (NPC 15951)
A solution of 1-methyl-9-fluorenemethanol (its synthesis has been described in Example 25; 7.4 g, 35.2 mmol) in a mixture of anhydrous THF and methylene chloride (1:1, 90 mL) was charged with a solution of 4.2 M phosgene in methylene chloride (17 mL, 70.4 mmol) at room temperature. The reaction mixture was stirred for 24 hr at room temperature, then the excess of the phosgene was removed by bubbling argon. The solvents were removed in vacuum. The resulting yellow oil of the crude 1- methyl-9-fluorenylmethyl chloroformate was devided into three identical portions of 11.7 mmol each.
The resulting oil of 1-methyl-9- fluorenylmethyl chloroformate was dissolved in dioxane (50 mL) then added to a solution of L- norleucine (2.9 g, 23.6 mmol) in a mixture of dioxane (50 mL) and 10% aqueous solution of
potassium carbonate (90 mL), at room temperature. The reaction mixture was stirred overnight, diluted with water and the organic impurities were extracted with ethyl acetate ( 5x30 mL) . The water layer was acidified to pH 1. The precipitate was filtered, washed with water and dried. Further purification on a short path chromatography (RP-18 Silica, from 50% to 70% methanol in water) afforded 2.1 g (16%) of the desired product, mp 130-135°C. EXAMPLE 38
N-{[9H-(1-Methylfluoren-9-yl)methoxy]carbonyl}-L- tert-leucine (NPC 15952)
A solution of 1-methyl-9-fluorenylmethyl chloroformate (prepared according to Example 37;
11.7 mmol) was dissolved in dioxane (50 mL) then added to a solution of L-norleucine (2.9 g, 23.6 mmol) in a mixture of dioxane (50 mL) and 10% aqueous solution of potassium carbonate (90 mL), at room temperature. The reaction mixture was stirred overnight, diluted with water and the organic impurities were extracted with ethyl acetate (5x30 mL). The water layer was acidified to pH 1. The precipitate was filtered, washed with water and dried. Further purification on a short path
chromatography (RP-18 Silica, from 50% to 70% methanol in water) afforded 2.05 g (15.6%) of the desired product, mp 78-81°C.
EXAMPLE 39
N-{[9H-(4-Methylfluoren-9-yl)methoxy]carbonyl}-L- homophenylalanine (NPC 15961)
A solution of 1-methyl-9-fluorenylmethyl chloroformate (prepared according to Example 37;
11.7 mmol) was dissolved in dioxane (50 mL) then added to a solution of L-homophenylalanine (4.23 g, 23.6 mmol) in a mixture of dioxane (50 mL) and 10% aqueous solution of potassium carbonate (90 mL), at room temperature. The reaction slurry was stirred overnight, diluted with water and acidified to pH 1. The resulting oil was purified on reverse phase
Short path chromatography (RP-18 Silica, from 60% to 75% methanol in water) afforded 2.5 g (17%) of the desired product, mp 104-119°C.
EXAMPLE 40
N-{9H-[3-(2-Methoxyfluoren-9-yl)propionyl]}- L-leucine (NPC 15968)
2-[(2-Methoxyfluoren-9-yl)ethyl]-1,3-dioxolane
A solution of n-BuLi (2.5 M in hexane, 6.4 mL, 16.0 mmol) was slowly added into a cooled (- 78°C) solution of 2-methoxyfluorene (prepared according to example 10; 3.1 g, 15.8 mmol) in 100 ml THF. The reaction mixture became dark red and a solid started to precipitate out. After 30 minutes 2-(2-bromoethyl)-1,3-dioxolane (5.8 g, 32.0 mmol) was added to the cold solution and the solution was warmed up to room temperature. The reaction mixture was stirred overnight at room temperature. TLC (silica, 25% EtOAc in hexane) was used to monitor the reaction. The reaction was quenched with water and the product was extracted into EtOAc. The organic layer was washed with water (x3), dried over magnesium sulfate and evaporated. Short path chromatography (5% ethyl acetate/hexane) afforded 3.2 g (62.5%) of the product.
3-(2-Methoxyfluoren-9-yl)propionic acid
A solution of 2-[(2-methoxyfluoren-9- yl)ethyl]-1,3-dioxolane (3.1 g, 10.0 mmol) in acetone (100 mL) at 0°C was charged with Jone's reagent (90 mL) (the reagent was made by dissolving 16 g of CrO3 and 16 ml of H2SO4 (cone.) in 100 ml of water). The reaction mixture was stirred overnight at room temperature. The reaction was monitored by
TLC (silica, 25% EtOAc in hexane). The acetone was evaporated, the residue was diluted with water (100 mL). The product was extracted into EtOAc and the organic layer was washed thoroughly with water (x6), until aqueous washings were clear, then the product was extracted into IN NaOH solution (3x50 mL), the water was washed again with ethyl acetate (1x30 mL) and acidified to pH=1. The oil formed was extracted with ethyl acetate. The ethyl acetate solution was v/ashed with water, brine, dried over magnesium sulfate and evaporated. The residue was dissolved in 25% ethyl acetate/hexane mixture and the solution was filtered through a layer of a coarse silica gel. Evaporation of the filtrate afforded 1.8 g (67.0%) of the 3-(2-methoxyfluoren-9-yl)propionic acid. 3-(2-Methoxyfluoren-9-yl)propionyl chloride
3-(2-Methoxyfluoren-9-yl)propionic acid (1.6 g, 5.2 mmol) was charged with SOC1, (20 mL, in excess) at room temperature. The reaction mixture was boiled for 2 hr. The reaction was monitored by TLC (silica RP-18, 70% methanol/water). The excess of thionyl chloride was removed under reduced pressure, the residue (an oil) was used for the next step without further purification. M-{9H-[3-(2-Methoxyfluoren-9-yl)propionyl]}-L- leucine
The compound above in 40 mL of dioxane was added to a stirred solution of L-leucine (1.3 g, 6.0 mmol) in 10% sodium carbonate solution (45 mL) and dioxane 21 mL) at room temperature. The reaction mixture was stirred overnight. The dioxane was removed under reduced pressure, the residue was diluted with water (100 mL), extracted with ethyl acetate (3x50 mL). The water solution was
acidified to pH 1. The oil was extracted with ethyl acetate. The solution was washed with water, brine, dried and evaporated. Short path chromatography (RP Silica, 60-65% methanol/water) afforded 0.85 g ( 44 . 3 % ) of N- { 9H- [ 3 - ( 2 -methoxyf luoren-9- yl ) propionyl ] } -L-leucine , mp 135-137 ° .
EXAMPLE 4 1
N-{9H-[3-(1-Methylfluoren-9-yl)propionyl]}- L-homophenylalanine (NPC-15974)
The compound 3-(1-methylfluoren-9- yl)propipnyl chloride (its preparation was described in Example 32; 4.0 g, 14.8 mmol) in 80 mL dioxane was charged with a solution of L-homophenylalanine (3.5 g, 19.5 mmol) in 20 mL of 10% aqueous solution of sodium carbonate at room temperature. The reaction mixture was stirred for two hours. Most of the dioxane was removed under reduced pressure. The residue was acidified, with HCl, to pH 1 and was extracted with ethyl acetate. The organic extract was concentrated and the crude product was purified via short path chromatography on reverse phase silica (RP-18 Silica, 25% then 70% methanol in water) to afforded 4.5 g (73%) of N-{9H-[3-(1- methylfluoren-9-yl)propionyl]}-L-homophenylalanine, mp 138-140°C.
EXAMPLE 42
N-{9H-[3-(4-Methylfluoren-9-yl)propionyl]}-L- leucine quarter hydrate (NPC 15975)
2-[(4-MethyIfluoren-9-yl)ethyl]-1,3-dioxolane
A solution of BuLi (2.5 M in hexane, 20.4 mL, 51.0 mmol) was slowly added into a cooled
(-78°C) solution of 4-methylfluorene (prepared according to Example 10; 9.0 g, 49.8 mmol) in 100 mL of THF. After 30 minutes 2-(2-bromoethyl)-1,3- dioxolane (18.9 g, 105.0 mmol) was added to the cold solution and the solution was warmed up to room temperature. The reaction mixture was stirred for weekend at room temperature. TLC (silica, 25% EtOAc in hexane) was used to monitor the reaction. The reaction was quenched with water and the product was extracted into EtOAc. The organic layer was washed with water (x3), dried over magnesium sulfate and evaporated. Short path chromatography (5% ethyl acetate/hexane) afforded 11.2 g(82.8%) of the product.
3-(4-Methylfluoren-9-yl)propionic acid
A solution of 2-[(4-methylfluoren-9- yl)ethyl]-1,3-dioxolane (11.1 g, 39.6 mmol) in acetone (150 mL) at 0°C was charged with Jone's reagent (16 g of CrO3 and 16 ml of H2SO4 (conc.) in 100 ml of water). The reaction mixture was stirred overnight at room temperature. The reaction was monitored by TLC (silica, 25% EtOAc in hexane). The acetone was evaporated, the residue was diluted with water (100 mL). The product was extracted into
EtOAc and the organic layer was washed thoroughly with water (x6), until aqueous washings were clear, then the product was extracted into 1N NaOH solution (3x70 mL), the water was washed again with ethyl acetate (1x30 mL) and acidified to pH=1. The solid formed was filtered off, washed with water and dried. This afforded 6.8 g (68.2%) of the 3-(4- methylfluoren-9-yl) propionic acid. 3-(4-Methylfluoren-9-yl)propionyl chloride
3-(4-Methylfluoren-9-yl)propionic acid (3.5 g, 13.9 mmol) was charged with SOCl, (20 mL, in excess) at room temperature. The reaction mixture was boiled for 2 hr. The reaction was monitored by TLC (silica RP-18, 70% methanol/water). The excess of thionyl chloride was removed under reduced pressure, the residue (an oil) was used for the next step without further purification.
N-{9H-[3-(4-Methylfluoren-9-yl)propionyl]}-L- leucine, quarter hydrate
The compound above in 40 mL of dioxane was added to a stirred solution of L-leucine (2.6 g,
20.0 mmol) in 10% sodium carbonate solution (90 mL) and dioxane (45 mL) at room temperature. The reaction mixture was stirred overnight. The dioxane was removed under reduced pressure, the residue was diluted with water (100 mL), extracted with ethyl acetate (3x50 mL). The water solution was acidified to pH 1. The solid was filtered off, washed with water and dried. Short path chromatography (RP Silica, 60-65% methanol/water) afforded 1.8 g
(36.0%) of N-{9H-[3-(4-methylfluoren-9- yl)propionyl]}-L-leucine, mp 125-127°C. EXAMPLE 43
N-{9H-[3-(1-MethyIfluoren-9-yl)propionyl]}- L-norleucine, quarter hydrate (NPC 15976) The compound 3-(1-methylfluoren-9- yl) propionyl chloride (its preparation was described in Example 32; 4.0 g, 14.8 mmol) in 80 mL dioxane was charged with a solution of L-norleucine (4.0 g, 30.5 mmol) in 20 mL of 10% aqueous solution of sodium carbonate at room temperature. The reaction mixture was stirred for two hours. Most of the dioxane was removed under reduced pressure. The residue was acidified, with HCl, to pH 1 and was extracted with ethyl acetate. The organic extract was concentrated and the crude product was purified via Short path chromatography on reverse phase silica (RP-18 Silica, 25% then 70% methanol in water) afforded 2.6 g (48%) of N-{9H-[3-(1- methylfluoren-9-yl)propionyl]}-L-norleucine, mp 128- 130°C.
EXAMPLE 44
Inhibition of Ear Edema Caused by Tetradecanoylphorbol Acetate (II)
CF-1 Mice, 25-30 g body weight, six animals per group were used. Test compounds were administered intraperitoneally or topically as follows. For intraperitoneal administration, the test compound v/as dissolved in dimethyl sulfoxide or 0.5% methylcellulose and 100 microliters was
injected 30 minutes prior to irritant (100 mg/kg, i.p.). For topical administration, the test
compound was dissolved in dimethyl sulfoxide, acetone, or ethanol and 5 microliters (100
micrograms) applied to the upper surface and an additional 5 microliters applied to the lower surface of the ear fifteen minutes prior to
application of the irritant. A solution of the irritant, tetradecanoylphorbol acetate, 200 μg/mL, was added to the surface of the ear, 5 μL to the upper surface and 5 μL to the lower surface. After three hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag,
positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the
inhibition of increased ear thickness compared to control animals receiving only the irritant. In general, % inhibition of equal to or greater than 20 % is statistically significant (p < 0.05, or less, Student's t-test for unpaired data) The results are reported in Table 7.
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
EXAMPLE 45
Inhibition of Ear Edema Caused by Arachidonic Acid (II)
CF-1 mice, 25-30 g body weight, six
animals per group, were used. The requisite amount of the test compound was dissolved is dimethyl sulfoxide or 0.5% methylcellulose and 100 μL of the solution was injected intraperitoneally 30 minutes prior to the administration of 100 mg/kg of
arachidponic acid. A solution of this irritant, 100 mg/mL in ethanol, was applied to the surface of the ear, 5 μL to the upper surface and 5 uL to the lower surface. After sixty minutes, the thickness of the ear was measured ot 0.01 mm by a micrometer with the loose drag positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the percent inhibityion by the test compound of increased ear thickness compared to control animals recieveing only the irritant. In general, %
inhibition of equal to or greater than 20% is
statistically significant (p, 0.05, or less,
Student's t-test for unpaired data). The results are reported in Table 8.
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
EXAMPLE 4 6
Inhibition of Ear Edema Caused by Xylene (II)
CF-1 mice, 25 -30 g body weight, six animals per group, were used. The requisite amount of the test compound was dissolved is dimethyl sulfoxide or 0.5% methylcellulose and 100 μL of the solution was injected intraperitoneally 30 minutes prior to the administration the irritant. The irritant xylene was applied to the surface of the ear, 20 μL to the upper surface and 20 μL to the lower surface. After two hours, the thickness of the ear was measured to 0.01 mm by a micrometer with the loose drag
positioned at the lateral-most edge of the midpoint of the pinna. Data were calculated as the percent inhibition by the test compound of increased ear thickness compared to control animals receiving only the irritant. In general, % inhibition of equal to or greater than 20 % is statistically significant (p < 0.05, or less, Student's t-test for unpaired data). The results are reported in Table 9.
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
EXAMPLE 47
Inhibition of Ear Edema Caused by
Oxazolone (II)
CF-1 mice, 25-30 g body weight, five to six animals per group were used. The mice were
sensitized to the irritant two weeks prior to the test by dribbling 100 μL of a 3% solution of
oxazolone in acetone onto the abdominal skin of the animal. Test compounds were administered
intraperitoneally as follows. The test compound was dissolved in dimethyl sulfoxide or 0.5%
methylcellulose and 100 microliters (100 mg/kg) was injected 30 minutes prior to irritant. The
irritant, 3% oxazolone in acetone, was added to the surface of the ear, 5 μL added to the upper surface and 5 μL added to the lower surface. After twenty four hours, the thickness of the ear was measured to 0.01 mm by a micrometer with loose drag, positioned at the lateral-most edge of the mid-point of the pinna. Data were calculated as the inhibition of increased ear thickness compared to control animals' receiving only the irritant. In general, %
inhibition of greater than 20% is statistically significant (p < 0.05 or less, Student's t-test for unpaired data). The results are reported in Table 10.
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
EXAMPLE 48
Reverse Passive Artus Reaction (II) Male CD rats weighing between 200 and 250 g were used. Test compounds were dissolved in
dimethyl sulfoxide and 200 μL of this solution (100 mg/kg) were injected intraperitoneally one hour before administration of the antigen. The animals were anesthetized inhalationally with isoflurane and then injected through the penile vein with 1 mL of a solution of 2.5 mg of Evan's blue dye and 5.0 mg of human serum albumin in 1 mL of saline. This
treatment was followed immediately by intracutaneous injections of 0.03 mL of anti-human albumin diluted to contain 3.65 mg of antibody at 3 sites along the midline back. Anesthesia was terminated and after three hours, the animals were sacrificed. The skin was removed and the blue stained areas cut out. The skin patches were soaked overnight in stoppered tubes containing 1 mL of 1 N potassium hydroxide at 37°C. Then 9 mL of a mixture of five parts of a 0.6 N phosphoric acid and thirteen parts of acetone were added to the tubes. The tube contents were agitated and centrifuged, and the absorbance
measured at 620 nm. The data were calculated as inhibition of blueing by test compound compared to control animals receiving only antigen and antibody. The results are reported in Table 11.
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
EXAMPLE 49
Adjuvant Arthritis Male Sprague Dawley rats, 150 - 200 g, were anesthetized with isoflurane. Drug was
administered intraperitoneally in 0.5%
methylcellulose or water. The rat was then injected in the distal third of the tail with 0.5 mL of saline or 0.5 mL of well-sonicated Freund's complete adjuvant containing 1 mg/mL Mycobacterium
tuberculosis. Rats were then returned to their cages. On days 1 and 2 after the adjuvant
injection, each rat was weighed and dosed with vehicle or drug suspension as before, but without anesthesia. On day 3, each rat was weighed and anesthetized. Blood was drawn by cardiac puncture into 0.2 mL of EDTΛ solution. Blood samples were microcentrifuged for 30 seconds. Then fibrinogen was converted into fibrin using sodium sulfite and the resulting fibrin was assayed using a Lowry protein assay to estimate initial fibrinogen levels. Percent inhibition by test compound was determined by subtracting fibrinogen level in non-Freund's adjuvant-injected rats from fibrinogen levels in rats injected with adjuvant alone and those rats injected with adjuvant plus test compound, and dividing the resultant fibrinogen increases in drug treated animals by non-drug treated animals and multiplying by 100.
Table 12
Inhibition of Adjuvant Induced Fibrinogen
Compound
NPC Number
% Inhibition
(dose, mg/kg)
N-[9H-(2,3-Denzofluoren-9-ylmethoxy)carbonyl]-L-loucinc (NPC 15510)
35(100)
N-((9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucino amide (NPC 15528)
0(100)
* * * *
For purposes of completing this disclosure, all references cited hereinabove are hereby incorporated by reference.
While the present invention has been described in some detail for purposes of clarity and
understanding, one skilled in the art on reading this disclosure will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.

Claims

WHAT IS CLAIMED IS:
1. A method of treating an inflammatory condition comprising administering to an animal in need of such treatment an amount of at least one compound represented by the following formula:
I
Figure imgf000088_0001
wherein:
X is methylene, ethylene, ethyleneoxy, methyleneoxy, or oxygen;
Q is where C' is a residue of a
Figure imgf000088_0002
Iipophilic amino acid, and Y is -CO2H, -CH2OH, -CONR1R2, or -CO2R1 where R1 and R2 are hydrogen, alkyl, or aryl;
R3 and R4 are, independently, hydrogen, alkyl or aryl; and
A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoκyalkyl, halogen, or nitro; or pharmaceutically acceptable salts thereof, sufficient to reduce or eliminate said inflammatory condition,
with the proviso that when A, B, R3, and R4 are hydrogen and Y is -CO2H or acceptable salts thereof, X is not oxygen,
and with the further proviso that when A or B are, independently, hydrogen or halogen, R3 and R4 are hydrogen, X is oxygen, and Y is -CO2H or acceptable salts thereof, C' is not an aromatic amino acid residue,
and further that when X is oxygen, at least one of A and B is not hydrogen, halogen or nitro.
2. The method according to claim 1 wherein at least one of said alkyl, aryl, fused phenyl, alkaryl, aralkyl, alkoxy or alkoxyalkyl groups is substituted with C1-4alkyl.
3. The method according to claim 1 wherein said animal is a mammal.
4. The method according to claim 1 wherein R1, R2, R3 and R4 are, independently, hydrogen, (C1-8) alkyl, or (C6-12) aryl; and A and B are, independently, hydrogen, fused phenyl, (C1-9)alkyl, (C6-12)aryl, (C1-9)alk(C6-12)aryl, (C6-12)ar(C1-9)alkyl, (C1-9)alkoxy, (C1-9)alkoxy(C1-9)alkyl, halogen, or nitro.
5. The method according to claim 4 wherein X is oxygen.
6. The method according to claim 5 wherein A, B, R3 and R4 are hydrogen.
7. The method according to claims 5 or 6 wherein C' is a L-leucine residue and Y is -OH2H.
8. The method according to claims 5 or 6 wherein C' is a L-phenylalanine residue and Y is -CO2H.
9. The method according to claim 6 wherein C' is a L-norleucine residue and Y is -CO2H.
10. The method according to claim 6 wherein C' is a S-benzyl-β,β-dimethyl-D-cystine residue and Y is -CO2H.
11. The method according to claim 6 wherein C is a L-tert-leucine residue and Y is -CO2H.
12. The method according to claim 6 wherein C' is a L-neopentylglycine residue and Y is -CO2H.
13. The method according to claim 5 wherein R3 and R4 are hydrogen, A or B are at least one alkyl group, and Y is -CO2H.
14. The method according to claim 13 wherein A is a methyl group located in the 4 position of the fluorene ring, B is hydrogen, and C' is a leucine residue.
15. The method according to claim 13 wherein A is a methyl group located in the 4 position of the fluorene ring, B is hydrogen, and C' is a homophenylalanine residue.
16. The method according to claim 13 wherein A is a methyl group located in the 2 position of the fluorene ring, B is a methyl group located in the 7 position of the fluorene ring, and C' is a leucine residue.
17. The method according to claim 1 wherein X is methylene.
18. The method according to claim 17 wherein Y is - CO2H.
19. The method according to claim 18 wherein A, B, R3 and R4 are hydrogen.
20. A compound of Formula I:
I
Figure imgf000091_0001
wherein:
X is methylene, ethylene, ethyleneoxy, methyleneoxy, or oxygen;
Q is where C' is a residue of a
Figure imgf000091_0002
Iipophilic amino acid, and Y is -CO2H, -CH2OH, -CONR1R2, or -CO2R1 where R1 and R2 are hydrogen, alkyl, or aryl; R3 and R4 are, independently, hydrogen, alkyl or aryl; and
A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro;
or pharmaceutically acceptable salts thereof, with the proviso that when A, B, R3, and R4 are hydrogen and Y is -CO2H or acceptable salts thereof, X is not oxygen,
and with the further proviso that when A or B arc, independently, hydrogen or halogen, R3 and R4 are hydrogen, X is oxygen, and Y is -CO2H or acceptable salts thereof, C' is not an aromatic amino acid residue,
and further that when X is oxygen, at least one of A and B is not hydrogen, halogen or nitro.
21. The compound according to claim 20 wherein at least one of said alkyl, aryl, fused phenyl, alkaryl, aralkyl, alkoxy or alkoxyalkyl groups is substituted with a C1-4alkyl.
22. The compound according to claim 20 wherein R1, R2, R3 and R4 are, independently, hydrogen, (C1-8) alkyl, or
(C6-12)aryl; and A and B are, independently, hydrogen, fused phenyl, (C1-9)alkyl, (C6-12)aryl, (C1-9)alk(C6-12)aryl, (C6-12)ar(C1-9)alkyl, (C1-9)alkoxy, (C1-9)alkoxy(C1-9)alkyl, halogen, or nitro.
23. The compound according to claim 22 wherein X is methylene or oxygen, A, B, R4 are hydrogen, and Y is - CO2H.
24. The compound according to claim 22 wherein R3, and R4 are hydrogen; and A or B is (C1-9) alkyl, Y is -CO2H, and Q is leucine, isoleucine, norleucine or phenylalanine.
25. The compound according to claim 24 wherein A is a methyl group in the 4 position of the fluorene ring, B is hydrogen, and C' is a leucine residue or a homophenylalanine residue.
26. The compound according to claim 25 wherein A is a methyl group located in the 2 position of the fluorene ring, B is a methyl group located in the 7 position of the fluorene ring, and C' is a leucine residue.
27. The compound according to claim 24 wherein X is ethylene, ethyleneoxy, mcthylenεoxy or oxygen, Y is - CONR1R2 and R3 and R4 are hydrogen.
28. The compound according to claim 27 wherein R1 is hydrogen and R2 is hydrogen, alkyl or aryl.
29. The compound according to claim 28 wherein R2 is methyl and Q is leucine.
30. The compound according to claim 22 wherein A, B, R3 and R4 are hydrogen, X is oxygen, Y is -CONHCH3 and Q is leucine.
31. The compound according to claim 22 wherein A is a methyl group in the 2 position of the fluorene ring, B is a methyl group in the 7 position of the fluorene ring, R3 and R4 are hydrogen, X is oxygen, Y is -CONHCO3 or -CO2H or salts thereof, and Q is leucine.
32. The compound according to claim 22 wherein A is a methyl group in the 4 position of the fluorene ring, B, R3 and R4 are hydrogen, X is oxygen, Y is -CO2H (or salts thereof) and Q is leucine.
33. The compound N-[9H-(fluoren-9-ylmethoxy) carbonyl]-L-tert-leucine.
34. The compound N-[9H-(fluoren-9-ylmethoxy) carbonyl]-L-neopentylglycine.
35. A pharmaceutical composition in dosage unit form suitable for use in producing an anti-inflammatory effect in an animal comprising, as an active ingredient, selected from claims 20 to 34 together with a pharmaceutically acceptable carrier or diluent.
36. A pharmaceutical composition in dosage unit form suitable for use in producing an anti-inflammatory effect in an animal comprising, as an active ingredient, an effective amount, of the compound of claim 26.
37. A method of treating an inflammatory condition comprising administering to an animal in need of such treatment an amount of least one compound represented by the following formula:
I
Figure imgf000095_0001
wherein:
X is methylene, ethylene, ethyleneoxy, or oxygen; Q is where C' is a residue of a
Figure imgf000095_0002
Iipophilic amino acid, and Y .is -CO2H, -CH2OH, -CONR1R2, or -CO2R1 where R1 and R2 are hydrogen, alkyl, or aryl;
R3 and R4 are, independently, hydrogen, alkyl or aryl; and
A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, aralkyl, alkoxy, alkoxyalkyl, halogen, or nitro; or pharmaceutically acceptable salt thereof, sufficient to reduce or eliminate said inflammatory condition.
38. A compound of Formula I:
I
Figure imgf000096_0001
wherein:
X is methylene, ethylene, ethyleneoxy, or oxygen; Q is where C' is a residue of a
Figure imgf000096_0002
Iipophilic amino acid, and Y is -CO2H, -CH2OH, -CONR1R2, or -CO2R1 where R1 and R2 are hydrogen, alkyl, or aryl;
R3 and R4 are, independently, hydrogen, alkyl or aryl; and
A and B are, independently, hydrogen, fused phenyl, alkyl, aryl, alkaryl, eralkyl, alkoxy, alkoxyalkyl, halogen, or nitro;
or pharmaceutically acceptable salt thereof, with the proviso that when A, B, R3, and R4 are hydrogen and Y is -CO2H (or salt thereof), X is not oxygen,
and with the further proviso that when A or B are, independently, hydrogen or halogen, R3 and R4 are hydrogen, X is oxygen, and Y is -CO2H (or salt thereof), C' is not an aromatic amino acid residue.
PCT/US1991/003319 1990-05-29 1991-05-17 Methods for treating inflammation and compounds and compositions suitable for use therein WO1991018596A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002083134A CA2083134A1 (en) 1990-05-29 1991-05-17 Methods for treating inflammation and compounds and compositions suitable for use therein
NO92924517A NO924517L (en) 1990-05-29 1992-11-24 METHODS FOR TREATMENT OF INFLAMMATION AND COMPOUNDS AND PREPARATIONS SUITABLE FOR USE THEREOF
FI925327A FI925327A0 (en) 1990-05-29 1992-11-24 FOERFARANDE FOER VAORD AV INFLAMMATION OCH I DESSA ANVAENDBARA FOERENINGAR OCH KOMPOSITIONER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/529,356 US5079260A (en) 1989-06-22 1990-05-29 Method for treating inflammation and compounds and compositions suitable for use therein
US529,356 1990-05-29

Publications (1)

Publication Number Publication Date
WO1991018596A1 true WO1991018596A1 (en) 1991-12-12

Family

ID=24109577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003319 WO1991018596A1 (en) 1990-05-29 1991-05-17 Methods for treating inflammation and compounds and compositions suitable for use therein

Country Status (11)

Country Link
US (1) US5079260A (en)
EP (1) EP0531443A4 (en)
JP (1) JPH05509299A (en)
AU (1) AU7951591A (en)
CA (1) CA2083134A1 (en)
FI (1) FI925327A0 (en)
IE (1) IE911823A1 (en)
IL (1) IL98223A0 (en)
NZ (1) NZ238272A (en)
WO (1) WO1991018596A1 (en)
ZA (1) ZA914102B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015105A1 (en) * 1994-11-15 1996-05-23 Italfarmaco S.P.A. Fluorenyl-hydroxamic derivatives endowed with immunosuppressive and anti-inflammatory activity
WO2002000611A2 (en) * 2000-06-29 2002-01-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
WO2004106363A2 (en) * 2003-05-30 2004-12-09 Css-Albachem Limited A tag for purification of peptides

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668230A (en) * 1991-07-23 1997-09-16 Phillips Petroleum Company Olefin polymerization
AU3239393A (en) * 1991-12-12 1993-07-19 Scios Nova Inc. Fluorenyl derivatives and their use as anti-inflammatory agents
US5472973A (en) * 1991-12-12 1995-12-05 Scios Nova Inc. Fluorenyl derivatives as anti-inflammatory agents
US5788982A (en) * 1995-06-16 1998-08-04 Nadoolman; Wolffe Method and composition for treating oral pain using capsaicin
DE60034667T2 (en) 1999-02-01 2008-03-13 Dermal Research Laboratories, Inc. PHARMACEUTICAL COMPOSITION OF COMPLEX CARBOHYDRATES AND THEIR USE
WO2001009117A1 (en) * 1999-07-29 2001-02-08 Allellix Neuroscience Inc. Tricyclic compounds as glycine transport inhibitors
US7879824B2 (en) * 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP2004530632A (en) * 2000-08-18 2004-10-07 ジェネンテック・インコーポレーテッド Integrin receptor inhibitor
CN100412060C (en) * 2005-01-27 2008-08-20 中国科学院大连化学物理研究所 Prepn of-2-(N-carbazolyl)-ethoxy carbohydrazide
DE102005062741A1 (en) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorenes and carbazoles as ligands of the EP2 receptor
CN101328136B (en) * 2008-07-23 2011-02-09 中国科学院广州化学研究所 Aminoacid acidamide compounds and preparation thereof
CN108774158A (en) * 2018-06-20 2018-11-09 南京肽业生物科技有限公司 A kind of reaction of Fmoc and hydrophobic amino acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835175A (en) * 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877269A (en) * 1956-04-17 1959-03-10 Wm S Merrell Co Guanyl substituted triphenylethanes, triphenylethylenes and benzalfluorenes
US3845097A (en) * 1969-09-06 1974-10-29 Ajinomoto Kk N-substituted amino acids and novel ester
NL7013043A (en) * 1969-09-06 1971-03-09
US3919291A (en) * 1969-09-06 1975-11-11 Ajinomoto Kk N-ethylcarbaminomethylisoleucine
US3906031A (en) * 1971-03-15 1975-09-16 Research Corp Novel 9-fluorenylmethoxycarbonyl compounds
EP0129075A3 (en) * 1983-05-20 1985-08-28 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Protected amino acid derivatives and their preparation
EP0288965A2 (en) * 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides with a phospholipase A2 inhibiting activity
JPH04506350A (en) * 1989-06-22 1992-11-05 ノバ　ファーマスーティカル　コーポレイション Pharmaceutical compositions for treating inflammation and methods for treating inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835175A (en) * 1971-03-15 1974-09-10 Research Corp 9-fluorenylmethanol haloformates, carbonates and thiocarbonates

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015105A1 (en) * 1994-11-15 1996-05-23 Italfarmaco S.P.A. Fluorenyl-hydroxamic derivatives endowed with immunosuppressive and anti-inflammatory activity
WO2002000611A2 (en) * 2000-06-29 2002-01-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
WO2002000611A3 (en) * 2000-06-29 2002-05-30 Ass Pour Le Dev De La Rech Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists
WO2004106363A2 (en) * 2003-05-30 2004-12-09 Css-Albachem Limited A tag for purification of peptides
WO2004106363A3 (en) * 2003-05-30 2005-05-26 Css Albachem Ltd A tag for purification of peptides

Also Published As

Publication number Publication date
EP0531443A4 (en) 1993-04-21
ZA914102B (en) 1993-02-24
FI925327A (en) 1992-11-24
NZ238272A (en) 1994-03-25
JPH05509299A (en) 1993-12-22
IE911823A1 (en) 1991-12-04
FI925327A0 (en) 1992-11-24
IL98223A0 (en) 1992-06-21
US5079260A (en) 1992-01-07
EP0531443A1 (en) 1993-03-17
AU7951591A (en) 1991-12-31
CA2083134A1 (en) 1991-11-30

Similar Documents

Publication Publication Date Title
WO1991018596A1 (en) Methods for treating inflammation and compounds and compositions suitable for use therein
EP0462884B1 (en) Trh derivatives, their preparations and pharmaceutical compositions containing them
HU215437B (en) Nitric esters having an inflammatory and anti-platelet aggregation activity and process for preparing them
JPH05310664A (en) Biaryl substituted 4-aminobutyric acid amide
CA1101846A (en) Derivatives of 4-hydroxy-phenylglycine
IT9021075A1 (en) BENZOIC ACID DERIVATIVES SUBSTITUTED FOR CARDIOVASCULAR ACTIVITY
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0721945B1 (en) Benzolactam derivative
EP0254354B1 (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
EP0177356B1 (en) Method for treatment of antidiuresis
US5472973A (en) Fluorenyl derivatives as anti-inflammatory agents
PT90254B (en) METHOD FOR PREPARING AMIDES OF CYCENOMETILENIC ACID-1,2-DICARBOXYL ACIDS WITH THERAPEUTIC ACTIVITY AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5519043A (en) Fluorenyl derivatives
US3676463A (en) Oxobenzofuran carboxamides
EP0309262B1 (en) Novel salicylates, their salts, pharmaceutical compositions containing them and process for preparing same
EP0124925B1 (en) Derivatives of d-2-(6-methoxy-2-naphthyl)-propionic acid having therapeutical activity, process for their preparation and pharmaceutical compositions containing them
SE434835B (en) N- (1-METHYL-2-PYRROLIDINYLMETHYL) -2,3-DIMETOXY-5-METHYLSULPHAMOYL-BENZAMIDE, ITS PREPARATION AND PHARMACOLOGICAL COMPOSITION CONTAINING THIS NEW BENZAMIDE
WO1990015602A1 (en) Pharmaceutical compositions and methods for treating inflammation
EP0430738A2 (en) Use of an imidazopyridine for the manufacture of anesthetic medicaments
KR930006195B1 (en) Buteroic acid amides, their salts, pharmacetutical compositions containing them and process for preparing same
IE58497B1 (en) New process for the preparation of derivatives of 4h-1, 2,4-triazole, the new triazoles so obtained, their use as medicaments and the pharmaceutical compositions containing them
US4795758A (en) 5-[2-(pyrrolidin-1-yl)ethoxy]-p-cymene derivatives, the process for the preparation of the said derivatives and drugs in which the said derivatives are present
SE460969B (en) APOVINCAMIC ACID DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES
KR880001007B1 (en) Process for the preparation of bicyclic compound
CH660480A5 (en) D-2- (6-METHOXY-2-NAFTIL) PROPIONIC DERIVATIVES WITH THERAPEUTIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2083134

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 925327

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 1991911551

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991911551

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991911551

Country of ref document: EP